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General introduction
Soft tissue sarcomas (STS) are relatively rare malignancies accounting for less than 1% of 
all cancers in adults, resulting in approximately 600-700 new cases in The Netherlands an-
nually.1 STS form a group of heterogeneous tumors which originate from mesenchymal 
progenitor cells. These progenitor cells show differentiation into various mesenchymal 
tissues, e.g. adipose tissue, fibrous tissue and muscle tissue, and over 50 histologic STS 
subtypes have been described in the latest World Health Organization classification.2,3 
The most common subtypes are pleomorphic undifferentiated sarcoma (including 
malignant fibrous histiocytoma), leiomyosarcoma, liposarcoma, malignant peripheral 
nerve sheath tumor and synovial sarcoma, which combined account for approximately 
three fourths of all STS.2 STS can occur at any anatomic location, while most commonly 
(50-60%) they arise in the extremities.2-4 Other common locations are the head/neck 
area, trunk and retroperitoneum. The etiology of most STS remains unknown. While, in 
rare cases STS development has been associated with preceding radiation therapy, im-
mune deficiency, viral infections and genetic and environmental factors.2 
The incidence of STS rises with increasing patients’ age and it shows a slight male pre-
dominance.2-5 The potential of STS to metastasize and thereby to influence patients’ sur-
vival and prognosis is mainly determined by the tumor grade and the histologic sub-
type.2,6,7 Lymfogenic metastases are rare,2,6 while hematogenic metastases, mainly to the 
lungs, are relatively common i.e. approximately 50% of all STS patients develop distant 
metastases during the course of their disease.8,9 Besides tumor grade and subtype, pa-
tients’ age and maximum tumor size have been shown to influence the development of 
distant metastases and (disease-specific) survival. Subsequently, these four parameters 
have been incorporated into various nomograms to predict patients’ outcome.10,11 
Prior to treatment, a MRI scan followed by a core-needle biopsy of the suspected lesion 
are performed, and combined they provide essential information needed for the diag-
nosis and accordingly for adequate treatment of the tumor. Benign soft tissue tumors, 
mostly lipomas, outnumber STS by 100:1.2 If a STS is diagnosed, a baseline chest CT scan 
is made to exclude lung metastases prior to the start of treatment. In extremity myxoid 
liposarcomas also a staging abdominal CT scan, to exclude abdominal metastases, is 
currently advised in the latest guidelines of the European Society for Medical Oncol-
ogy.12 In case of distant metastases at diagnosis, curative-treatment is no longer feasible 
in most STS, except in a few chemosensitive subtypes as embryonal rhabdomyosarco-
ma.2 However, the role of (neo)adjuvant systemic chemotherapy in the non-metastatic 
setting in most subtypes remains controversial and is under on-going investigation.13-15
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Treatment of localized extremity soft tissue sarcomas (ESTS)
Historically the treatment of non-metastatic (localized) ESTS comprised amputation of 
the affected limb. However, patients who underwent limb-amputation were shown to 
have similar survival rates when compared with patients who underwent limb-spar-
ing surgery (LSS) combined with external beam radiotherapy (EBRT).16-19 Accordingly, 
limb-sparing treatment has become the treatment of choice in localized ESTS since 
the 1980s. EBRT has been used regularly in addition to LSS to gain local control, and 
local control rates of 90% can be achieved nowadays.19-25 The timing of the EBRT has 
been studied extensively, and no differences in patients’ survival were found between 
preoperatively and postoperatively irradiated patients.21,26-30 Besides, EBRT might not be 
essential to obtain local control in some carefully selected patients, i.e. in case of low-
grade tumors which are resected with a >1cm resection margin.31,32 The data available 
addressing the association between local recurrence development, and subsequently 
the development of distant metastases and/or the risk for (disease-specific) death are 
contradictory. Hence, local recurrence development was found to be a predictor for 
the development of distant metastases and (disease-specific) death in some studies, 
while this finding was not confirmed in other studies.24,33-40 
At diagnosis, some ESTS are deemed primarily non-resectable or locally advanced, 
mainly due to tumor size, proximity to vital structures and/or bony involvement. In 
these cases, a multimodality treatment-approach consisting of hyperthermic isolated 
limb perfusion (HILP), surgical resection and in some cases EBRT has been used in over 
40 sarcoma centers throughout Europe.41 Using this multimodality treatment, local tu-
mor control can be achieved resulting in a limb-salvage rate of approximately 80-90% in 
these patients who would otherwise be considered for limb-amputation.42-47
Assessment of treatment efficacy
Over time, the treatment of ESTS improved and changed from limb-amputation into 
a more limb-sparing approach. This approach is based on a multimodality treatment-
setting, e.g. neoadjuvant EBRT, systemic chemotherapy and/or HILP have been used to 
achieve optimal local control and to prevent limb-amputation, even in locally advanced 
ESTS.44,46,48 Neoadjuvant treatment-regimens are used in daily-practice, and as a con-
sequence multiple studies were conducted to establish the changes in these tumors 
during and following the treatment. 
Since the 1990s, fluorine-18-fluorodeoxyglucose positron emission tomography with 
computed tomography (18F-FDG PET-CT) scans have been used to study the changes 
in metabolic tumor activity induced by HILP in locally advanced ESTS.49 Furthermore, 
baseline 18F-FDG PET-CT scans as well as scans following neoadjuvant chemotherapy 
have been used to predict patients’ survival.50-52 Besides the assessment of the metabolic 
tumor activity of the tumor prior to and following neoadjuvant treatment, the histolog-
ic appearance of the tumor at histopathological examination has been studied. It was 
shown that the percentage of tumor necrosis following neoadjuvant treatment does 
not predict patients’ survival,53 as treatment-induced necrosis cannot be distinguished 
from tumor necrosis already present at diagnosis. Therefore, the percentage of viable 
tumor cells in pretreated STS might have more predictive value for survival. Recently, 
the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone 
Sarcoma Group (EORTC-STBSG) published recommendations regarding the histopatho-
logical examination of pretreated STS,54 including a 5-tier STS response score based on 
the percentage of stainable, possibly viable, tumor cells.
Outline of this thesis
Part I - Treatment of resectable extremity soft tissue sarcoma
In resectable ESTS, wide surgical resection of the tumor is the mainstay of treatment. In 
addition, (neo)adjuvant EBRT is commonly used to achieve local tumor control. How-
ever, EBRT use harbors an increased wound complication risk, especially in the preop-
erative setting. Chapter 2 aims to identify predictors for wound complications following 
radiotherapy and surgical resection in ESTS treatment. 
Part II - Treatment of locally advanced extremity soft tissue sarcoma 
This part highlights the treatment of locally advanced ESTS. At first, a new treatment reg-
imen, consisting of neoadjuvant HILP, preoperative radiotherapy and surgery for locally 
advanced ESTS is described (chapter 3). Subsequently, the indications for amputation 
and the oncological outcome i.e. local control and survival, following limb-amputation 
in (locally advanced) ESTS are determined in chapter 4. 
Part III - Metabolic and histopathological tumor responses in pretreated 
extremity soft tissue sarcoma
This part addresses the metabolic and histopathological tumor responses in pretreated 
ESTS. Chapter 5 discusses the use of various volume of interest delineation techniques 
to study and quantify the changes in metabolic tumor activity using 18F-FDG PET-CT 
scans during the multimodality neoadjuvant ESTS treatment as described in chapter 3. 
Chapter 6 evaluates the histopathological tumor response, based on the percentage of 
stainable tumor cells, of pretreated ESTS using the EORTC-STBSG response score. 
Summary and conclusions of this thesis are presented in English and in Dutch (chap-
ter 7). Lastly, chapter 8 provides a view on the future perspectives of ESTS treatment. 
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In extremity soft tissue sarcoma (ESTS), external beam radiothera-
py (EBRT) has been used in addition to limb-sparing surgery (LSS). 
This study aims to identify predictors for major wound complica-
tion (MWC) development following EBRT and LSS in ESTS. 
Methods
This retrospective study includes ESTS patients treated with EBRT 
and LSS between 2005 and 2017. Two groups were formed; Group 
I included preoperatively irradiated patients, whereas Group II in-
cluded patients who underwent postoperative EBRT. Multivariate 
logistic regression analyses were performed to create a prediction 
model for MWC development.
Results
One hundred twenty-seven patients were included, 58 patients 
(45.7%) in Group I and 69 patients (54.3%) in Group II. Some differ-
ences in baseline characteristics were found between the groups, 
e.g. in tumor size and grade, histological subtype and total RT 
dose. Twenty-three patients (39.7%) in Group I and 14 patients 
(20.3%) in Group II developed a MWC (p=0.02). Preoperative EBRT 
was identified as independent predictor for MWC development, 
OR 2.75 (95%CI 1.21-6.26), p=0.02. Furthermore, a trend towards an 
increased MWC risk was shown for patients’ age (OR 1.02 (0.99-
1.04)), delayed wound closure (OR 3.20 (0.64-16.02)) and negative 
surgical margins (OR 2.26 (0.72-7.11)). The area under the curve 
(AUC) of the model was 0.68 (0.57-0.79). 
Conclusions
This study corroborates the increased MWC risk following preop-
erative EBRT in ESTS. It remains important to carefully weigh the 
MWC risk against the expected long-term functional outcome, 
and to consider the liberal use of primary plastic surgical recon-
structions in an individualized multidisciplinary tumor board prior 
to treatment.
Introduction
Annually, approximately 600-700 patients are diagnosed with a soft tissue sarcoma 
(STS) in The Netherlands.1 STS are heterogeneous tumors including multiple histo-
pathologic subtypes. Approximately 50-60% of the STS arise in the extremities.2,3
In the past, extremity soft tissue sarcoma (ESTS) treatment traditionally involved limb-
amputation. However, comparable disease-free and overall survival rates were shown 
for patients treated either with amputation or wide local excision and postoperative 
radiotherapy.4,5 Therefore, limb-sparing treatment for ESTS has been the treatment of 
choice.
External beam radiotherapy (EBRT) has been used in addition to limb-sparing surgery 
(LSS) to gain local control in ESTS patients; a local control rate of 90% can be achieved 
nowadays.5-9 However, despite extensive studying no significant differences in local 
control and survival between patients treated either with preoperative or postopera-
tive EBRT and LSS have been shown to date.10-15 So, the timing of the EBRT has been 
subject of debate. Nonetheless, the limb-sparing treatment of ESTS has undergone a 
gradual transition from postoperative to preoperative EBRT at our institution, mainly 
based on the data provided by the randomized trial by O’Sullivan et al.11 The predomi-
nant disadvantages of postoperative EBRT may be the larger radiation fields, higher 
radiation doses and the increased risk for long-term fibrosis.14 Accordingly, the use of 
preoperative EBRT has been advocated for two reasons; smaller radiation fields and 
lower total radiation doses, possibly leading to an improved functional outcome.16 The 
predominant disadvantage of preoperative EBRT is the increased risk for postopera-
tive wound complications.10,11,14,17,18 
The current study aims to identify predictors for the development of postoperative 
wound complications in ESTS patients following pre- or postoperative EBRT and LSS. 
Methods
Patients
The Institutional Review Board approved this retrospective study (case number 
2016.676). This study includes ESTS patients over 18 years of age who underwent ei-
ther pre- or postoperative EBRT and LSS at the University Medical Center Groningen 
(UMCG) between January 2005 and December 2016. All patients were treated with 
curative intent. Patients with ‘locally advanced’ ESTS treated with a combination of 
hyperthermic isolated limb perfusion, surgical resection and radiotherapy were ex-
2. Wound complications following radiotherapy
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cluded.19,20 Furthermore patients with a medical history of Li-Fraumeni syndrome or 
neurofibromatosis were excluded. Relevant data were obtained from patient medical 
records. Patients’ age at start of treatment is presented, and the maximum tumor di-
ameter prior to start of treatment was used as tumor size. Tumor location was deter-
mined as follows: lower leg including the knee, upper leg including the hip, lower arm 
including the elbow and upper arm including the shoulder. 
Prior to treatment, all STS patients are presented in a multidisciplinary sarcoma tu-
mor board to discuss the appropriate treatment strategy for each patient. Two groups 
were identified; Group I included patients treated with preoperative EBRT and LSS, 
whereas Group II included patients treated with postoperative EBRT and LSS. All STS 
patients treated at the UMCG are referred to and treated by a physiotherapist and a 
rehabilitation specialist to optimize functional outcome following their treatment. 
Radiotherapy
All patients underwent EBRT, either in the pre- or postoperative setting. Three-dimen-
sional conformal radiotherapy (3D-CRT) was delivered with a 6-15 MV linear accelera-
tor after patient-specific immobilization, bolus material was applied along the surgi-
cal scar. One patient was treated with intensity modulated radiotherapy (IMRT). For 
Group I, the diagnostic MRI scan was fused with the radiotherapy planning CT scan 
to obtain gross tumor volume (GTV), clinical target volume (CTV) and planning target 
volume (PTV). For Group II, the preoperative MRI scan, planning CT scan, surgical scar 
and markers (left at the surgical bed during the surgical resection) were used to obtain 
the clinical target volume (CTV) and planning target volume (PTV). 
Delineation of the tumors was performed as described in the review by Haas et al.14 
Although these recommendations were published in 2012, they were already in use 
before that time. For Group I this meant that the CTV was constructed by expanding 
the GTV by 4 cm in the longitudinal direction and 1.5 cm in the other directions. Next, 
the PTV was obtained by expanding the CTV by 1.0 cm in all directions. The total radia-
tion dose in Group I was 50 Gy (25x2 Gy). In case of a positive surgical margin following 
preoperative EBRT, no postoperative boost was considered, as this does not seem to 
influence local control rates.21
For Group II, the CTV was acquired by expanding the surgical volume by 4 cm in the 
longitudinal direction and 1.5 cm in all other directions. Next, the PTV was obtained by 
expanding the CTV by 1.0 cm in all directions. The postoperative EBRT was completed 
with a 5x2 Gy boost to the tumor bed, resulting in a total postoperative radiation dose 
of 60 Gy. A boost of 10x2 Gy was applied in case of a R1/R2 resection. 
Limb-sparing surgery (LSS)
For Group I, LSS was scheduled to take place six weeks after completion of the EBRT, 
whereas for Group II the EBRT was planned to start 6-8 weeks after the LSS, provided 
sufficient wound healing. Plastic surgical reconstructions were performed when in-
dicated, e.g. for primary wound closure or following a wound complication requiring 
secondary wound closure. The Union for International Cancer Control “R classification” 
was used to classify the ‘quality’ of the resection.22 
All complications, either medical or surgical, occurring within 120 days of LSS were 
analyzed and scored according to Clavien-Dindo.23 Furthermore, the occurrence of 
major wound complications (MWC) was monitored. A MWC was defined as a wound 
complication requiring any of the following, based on the study by O’Sullivan et al.11 
First, requiring a surgical intervention for wound repair e.g. debridement, abscess 
drainage and secondary wound closure through plastic surgical flap reconstruction or 
split skin graft (SSG). Second, requiring non-surgical wound management including: 
invasive procedure with or without regional anesthesia (e.g. seroma aspiration), read-
mission for the intravenous administration of antibiotics. Third, requiring persistent 
deep wound packing (>120 days) or requiring hyperbaric oxygen therapy to obtain 
wound closure. As hyperbaric oxygen treatment is intensive and generally takes 30-40 
daily sessions, these wound complications were included as MWC. Furthermore, these 
wound complications were scored as a grade IIIa complication.23
Typing and grading of all histopathologic specimens, either diagnostic core needle 
biopsies or specimens following LSS, were performed and defined according to WHO 
and American Joint Committee on Cancer criteria.24,25
Statistical analyses
Discrete variables are presented with frequencies and percentages and continuous vari-
ables with medians and interquartile ranges. Mann-Whitney U test was used to com-
pare continuous and ordinal variables. Fisher’s exact or chi-square test were used when 
appropriate to compare nominal variables, p-values <0.05 indicating statistical signifi-
cance. Multivariate logistic regression analyses was performed to create a prediction 
model for MWC development. Potential predictors were included in a first multivariate 
logistic regression model. Backward selection was used, and predictors with a p<0.2 
were included in the model, 1000x bootstrapping was performed. Odds ratios (OR) and 
95% confidence intervals (95% CI) are presented for the model. Subsequently, the area 
under the curve (AUC) was calculated to determine the predictive value of the final 
model. SPSS Version 23.0 (IBM SPSS Statistics for Windows, Version 23.0 Armonk, NY: IBM 
Corp) and Stata/SE version 12.0 (StataCorp, Texas, USA) were used for statistical analyses. 
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Results
A total of 127 patients, 74 male (58.3%) and 53 female (41.7%) with a median age of 62.0 
(48.0-73.0) years, were included. Group I included 58 patients (45.7%) and Group II in-
cluded 69 patients (54.3%). Patients in Group I had larger tumors which were more often 
of low grade. An unequal distribution of histological subtypes was observed among 
the groups. Accidental marginal resections performed at referring institutions account 
for the difference in local tumor presentation. No differences at baseline were found for 
age, gender, body mass index (BMI), smoking, diabetes mellitus and distant presenta-
tion (Table 1). Two patients in Group II were diagnosed with regional disease at presenta-
tion. Both were diagnosed with a lymph node metastasis, and were treated with cura-
tive intent by a lymph node dissection in addition to the LSS and postoperative EBRT. 
The distribution of patients according to the year of treatment differed significantly 
among the two groups (p<0.001). Between 2005 and 2007, one patient underwent 
preoperative EBRT while 35 patients underwent postoperative EBRT in this time pe-
riod. Whereas, 35 patients underwent preoperative EBRT and four patients underwent 
postoperative EBRT between 2014 and 2016. In Group I, the median time between 
completion of EBRT and LSS was 7.0 (6.0-9.3) weeks. In Group II the median time be-
tween LSS and start of EBRT was 6.0 (5.0-7.0) weeks. Total EBRT dose differed between 
Table 1. Patient, tumor and disease characteristics
Characteristic Group I (n=58) Group II (n=69) p-value
Age (years) 58.0 (45.8-68.3) 65.0 (52.0-74.0) 0.066
Gender 0.774
•	 Female 25 (43.1) 28 (40.6)
•	 Male 33 (56.9) 41 (59.4)
BMI 26.9 (23.6-30.0) 25.6 (23.9-27.8) 0.349
Smoking* 0.502
•	 No 49 (84.5) 62 (89.9)
•	 Yes 8 (13.8) 7 (10.1)
Diabetes mellitus 0.582
•	 No 53 (91.4) 61 (88.4)
•	 Yes 5 (8.6) 8 (11.6)
Tumor size (cm) 8.0 (5.8-11.0) 5.0 (3.0-8.0) <0.001
Tumor grade# <0.001
•	 Low 22 (37.9) 8 (11.6)
•	 High 35 (60.3) 60 (87.1)
Tumor location 0.086
•	 Lower leg 15 (25.9) 15 (21.7)
•	 Upper leg 35 (60.3) 31 (44.9)
•	 Lower arm 3 (5.2) 9 (13.0)
•	 Upper arm 5 (8.6) 14 (20.3)
Table 1. Continued
Characteristic Group I (n=58) Group II (n=69) p-value
Histological subtype <0.001
•	 Myxoid liposarcoma 22 (37.9) 4 (5.8)
•	 Leiomyosarcoma 5 (8.6) 8 (11.6)
•	 Myxofibrosarcoma 17 (29.3) 23 (33.3)
•	 Pleomorphic/NOS 8 (13.8) 15 (21.7)
•	 Synovial sarcoma 0 (0) 7 (10.1)
•	 MPNST 1 (1.7) 3 (4.3)
•	 Other 5 (8.6) 9 (13.0)
Local presentation <0.001
•	 First 55 (94.8) 47 (68.1)
•	 Recurrent 2 (3.4) 4 (5.8)
•	 R2 resection elsewhere 1 (1.7) 18 (26.1)
Distant presentation 0.500
•	 M0 58 (100.0) 67 (97.1)
•	 M1 0 (0) 2 (2.9)
Data presented as: n (%); median (interquartile range). Group I: preoperative EBRT; Group II: postop-
erative EBRT. *Data for one patient in Group I missing. #Data missing for one patient in both groups. 
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Group I and II (p<0.001), and the operation time was longer for patients in Group I, 
91.0 (58.0-129.5) vs. 70.0 (48.0-103.0) minutes, p=0.027. No differences considering EBRT 
technique (3D-CRT vs. IMRT), resection quality, timing or type of wound closure and 
the use of reconstructive surgery, either primary or secondary, were found. Among 
the series, a total of seven patients (5.5%) underwent delayed wound closure awaiting 
the final pathology report. Primary wound closure was achieved in 47 patients (81.0%) 
and 58 patients (84.1%) in Group I and II respectively. A split skin graft was used for 
wound closure in five patients (8.6%) in Group I and in eight patients (11.6%) in Group 
II. Vascularized tissue was used for wound closure in the remaining six patients (10.3%) 
in Group I and three patients (4.3%) in Group II. However, in Group I an extra two pa-
tients ultimately required reconstructive surgery to obtain wound closure due to the 
development of a MWC (13.8% in total in Group I) (Table 2).
Table 2. Treatment-related characteristics
Characteristic Group I (n=58) Group II (n=69) p-value
Year of treatment <0.001
•	 2005-2007 1 (1.7) 35 (50.7)
•	 2008-2010 10 (17.2) 21 (30.4)
•	 2011-2013 12 (20.7) 9 (13.0)
•	 2014-2016 35 (60.3) 4 (5.8)
Operation time (min) 91.0 (58.0-129.5) 70.0 (48.0-103.0) 0.027
Size resection specimen  
(cm, diameter)
13.0 (9.0-16.0) 11.5 (7.0-15.8) 0.135
Total EBRT dose* (Gy) 50.0 (50.0-50.0) 60.0 (60.0-70.0) <0.001
EBRT technique 0.457
•	 3D-CRT 57 (98.3) 69 (100)
•	 IMRT 1 (1.7) 0 (0)
Resection quality, tumor margin 0.406
•	 R0 48 (82.8) 54 (78.3)
•	 R1 10 (17.2) 13 (18.8)
•	 R2 0 2 (2.9)
Timing wound closure 0.701
•	 Direct 54 (93.1) 66 (95.7)
•	 Delayed awaiting pathology 
report
4 (6.9) 3 (4.3)
Table 2. Continued
Characteristic Group I (n=58) Group II (n=69) p-value
Type wound closure 0.386
•	 Primary 47 (81.0) 58 (84.1)
•	 Split skin graft 5 (8.6) 8 (11.6)
•	 Vascularized tissue 6 (10.3) 3 (4.3)
Reconstructive surgery  
(primary or secondary)
0.059
•	 No 50 (86.2) 66 (95.7)
•	 Yes 8 (13.8) 3 (4.3)
Timing reconstructive surgery
•	 Direct 4 3
•	 Secondary awaiting final 
pathology report
2 0
•	 Secondary due to MWC 2 0
Type reconstructive surgery
•	 Free flap 1 0
•	 Pedicled flap 7 3
Data presented as: n (%); median (interquartile range). Group I: preoperative EBRT; Group II: postop-
erative EBRT. *All patients in Group I underwent 50 Gy (25x2Gy) EBRT. In Group II: 67 patients (97.1%) 
underwent 60-70 Gy EBRT. One patient in Group II underwent an hyperfractionated EBRT schedule 
of 30x1.8 Gy resulting in a total dose of 54 Gy. The second patient developed a local recurrence and 
distant metastases during the postoperative radiation therapy and the EBRT was aborted after a 
local palliative dose of 50 Gy. Abbreviations: EBRT=external beam radiotherapy; 3D-CRT=three-di-
mensional conformal radiotherapy; IMRT=intensity modulated radiotherapy. 
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Table 3. Complications for Group I and II according to Clavien-Dindo23 
Group I (n=58) Group II (n=69) p-value
Total amount of complications 53 42
Grade I 10 (18.9) 11 (26.2)
Medical 2 2
•	 Collapse 1 0
•	 Urinary retention 1 2
Surgical 8 9
•	 Seroma 4 6
•	 Neuropraxia 2 1
•	 Delayed wound healing 1 2
•	 Hematoma 1 0
Grade II 18 (34.0) 14 (33.3)
Medical 4 5
•	 Atrial fibrillation 2 0
•	 Anemia 1 2
•	 Pulmonary embolism 1 1
•	 Deep venous thrombosis 0 1
•	 Urinary tract infection 0 1
Surgical 14 9
•	 Infection needing oral antibiotics 11 7
•	 Infection needing intravenous  
antibiotics 
3 0
•	 Delayed wound healing 0 1
•	 Split skin graft loss* 1
Table 3. Continued
Group I (n=58) Group II (n=69) p-value
Total amount of complications 53 42
Grade IIIa 9 (17.0) 12 (28.6)
•	 Infection 2 4
•	 Seroma 2 5
•	 Wound dehiscence 0 1
•	 Hematoma 0 2
•	 Delayed wound healing  
(hyperbaric O2)
5 0
Grade IIIb 12 (22.6) 5 (11.9)
•	 Infection 9 1
•	 Total flap loss 1 0
•	 Partial flap necrosis 1 0
•	 Postoperative bleeding 1 3
•	 Compartment syndrome 0 1
Grade IV 2 (3.8) 0 (0)
•	 Systemic sepsis 1 0
•	 Postoperative arterial bleeding 1 0
Grade V 2 (3.8) 0 (0)
•	 Systemic sepsis 1 0
•	 Esophageal ischemia 1 0
Total patients developing  
a complication 34 (58.6) 35 (50.7) 0.475
Patients developing a MWC 23 (39.7) 14 (20.3) 0.020
Data presented as: n (%); Group I: Preoperative EBRT; Group II: Postoperative EBRT. *The split skin graft 
used for wound closure was lost and removed during an outpatient clinic visit, resulting in delayed 
wound healing. The complications accounting for the MWCs are indicated in bold italic for both 
groups. 
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Complications 
A total of 53 complications in Group I and 42 complications in Group II occurred. Thirty-
four patients (58.6%) in Group I and 35 (50.7%) in Group II developed at least one com-
plication (p=0.475). Fifteen patients (25.9%) in Group I and six patients (8.7%) in Group 
II developed >1 complication. Grade II was the predominant complication grade for 
both groups. Twenty-three patients (39.7%) in Group I and 14 patients (20.3%) in Group 
II developed a MWC (p=0.02) (Table 3). 
The following variables: age, gender, local presentation, histologic subtype, tumor lo-
cation, tumor size, tumor grade, BMI, smoking, diabetes, operation time, type wound 
closure, timing wound closure (delayed vs. direct), reconstructive surgery (only in-
cluding patients for whom vascularized tissue was used for initial wound closure), 
radiotherapy timing (preoperative vs. postoperative), and tumor margin (R0 vs. R1/
R2) were included in the initial model. Multivariate analyses identified preoperative 
EBRT as predictor for MWC development, OR 2.75 (1.21-6.26), p=0.02. A trend towards 
an increased MWC risk was found for age OR 1.02 (0.99-1.04), p=0.18, timing of wound 
closure (delayed vs. direct) OR 3.20 (0.64-16.02), p=0.16 and tumor margins (R0 vs. R1/
R2) OR 2.26 (0.72-7.11), p=0.16 (Table 4). The predictive value of this model i.e. the AUC 
is 0.68 (0.57-0.79) (Figure 1).
Discussion
This study shows a significantly increased MWC risk following preoperative EBRT and 
LSS in ESTS, as nearly 40% of the patients in Group I and 20.3% of the patients in 
Group II developed a MWC (p=0.02). Multivariate logistic analyses identified preop-
erative EBRT as significant predictor for MWC development. This finding corroborates 
earlier reported data.11,14,17,26 Furthermore, a trend towards an increased MWC risk was 
shown for elderly patients, patients who underwent an R0 resection and patients who 
underwent delayed wound closure.
Table 4. Final prediction model for the development  
of a major wound complication
Predictor OR 95% CI p-value
Radiotherapy timing 0.02
•	 Postoperative 1
•	 Preoperative 2.75 1.21-6.26
Age, continuous 1.02 0.99-1.04 0.18
Timing wound closure 0.16
•	 Direct 1
•	 Delayed 3.20 0.64-16.02
Tumor margins 0.16
•	 R1/R2 1
•	 R0 2.26 0.72-7.11
Data presented as OR and 95% CI, age in years. Abbreviations: OR=odds ratio; 
CI=confidence interval. 
Figure 1. Receiver operating characteristic (ROC) curve for the development 
of a major wound complication. Area under the curve is 0.68 (0.57-0.79). 
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ESTS patients’ survival is not influenced by the timing of the EBRT.11-15 Therefore, the 
rationale for the timing of EBRT has been based on patient specific variables. These 
variables comprise expected short- and long-term treatment-induced morbidity e.g. 
tumor size, tumor depth, radiation dose, timing of the EBRT and also tumor histol-
ogy i.e. the proven radiosensitivity of myxoid liposarcomas. During preoperative EBRT 
the tumor volume of some STS increases, however, this increase in volume does not 
seem to influence local control rates.27 Several studies, including the randomized trial 
by O’Sullivan et al., showed significantly more acute wound complications following 
preoperative EBRT when compared to postoperative EBRT. These studies show that 
approximately 30-35% of the preoperatively irradiated patients develop a postopera-
tive MWC, compared to approximately 10-20% of patients following postoperative 
EBRT.10,11,14,17,18,26 On the contrary, due to the often larger radiation field-size and higher 
radiation dose, postoperative EBRT is associated with higher risk of fibrosis, joint stiff-
ness and edema during long-term follow-up. The presence of these late complica-
tions leads to an impairment in patients’ functional outcome.16 
At our institution a tendency towards the use of preoperative EBRT has taken place 
during the last years. Hence, in the current study only one of the 36 patients treated 
between 2005 and 2007 underwent preoperative EBRT, whereas 35 of the 39 patients 
treated between 2014 and 2016 underwent preoperative EBRT. Preoperative EBRT 
seems supported by a recent cost-effectiveness analysis, due to more costly post-
operative EBRT-induced long-term morbidity.28 However, there are also data show-
ing that patients’ functional outcome is adversely affected by the development of a 
postoperative MWC.29,30 Therefore, the cost-effectiveness of preoperative radiotherapy 
might be questioned. 
In myxoid liposarcoma, preoperative EBRT has become standard due to its proven 
radiosensitivity.31,32 Accordingly, a radiotherapy dose reduction study in myxoid lipo-
sarcoma (NCT02106312) was initiated and first results are awaited. This dose reduction 
of preoperative EBRT (total dose of 36 Gy) might subsequently result in a decreased 
MWC risk in this specific histological subtype. Besides dose reduction, preoperative 
hypofractionated EBRT (5x5 Gy) followed by LSS within one week also seems to be 
effective in myxoid liposarcoma.33 
Hypofractionated EBRT has been studied and used more commonly in other cancers, 
e.g. breast and rectal cancer.34,35 Data on hypofractionated EBRT in extremity and trunk 
STS is scarce. A study by Kosela et al. showed that oncological outcome was compa-
rable following 5x5 Gy hypofractionated preoperative EBRT and LSS within one week, 
when compared with the commonly used 25x2 Gy regimen.36 Only 7% of the patients 
in this study required a surgical intervention for the treatment of a wound complica-
tion. Furthermore, preoperative hypofractionated EBRT in STS is under ongoing inves-
tigation in a phase II trial (NCT02701153), of which the preliminary results were recently 
presented at the Connective Tissue Oncology Society Annual Meeting, 2017, showing 
a MWC rate of 17% in these patients.37
The current study has some limitations. The small sample size and the retrospective 
nature of the study harbors the risk of selection bias and missing data. Unfortunate-
ly, we were unable to identify and include the patients who were scheduled for LSS 
and postoperative EBRT, but who failed to undergo the scheduled EBRT. However, 
we were able to retrieve the patients who were scheduled for preoperative EBRT and 
LSS who did not undergo LSS. These 8 patients underwent preoperative EBRT, but 
failed to undergo LSS due to various reasons i.e. local tumor progression during the 
preoperative EBRT resulting in a non-resectable tumor in one patient, development of 
distant metastases during EBRT resulting in a palliative setting in five patients and de-
clining health status during EBRT resulting in a situation in which LSS was not feasible 
in two patients. Although all patients were referred to and treated by a physiothera-
pist and a rehabilitation specialist, no standardized long-term functional outcome was 
obtained. Therefore, we were unable to include patients’ functional outcome in this 
study. Moreover, there were some differences in baseline- and treatment characteris-
tics between both groups. Patients in Group I had larger tumors, which might explain 
the longer operation time, but more importantly this might also partly explain the 
higher amount of MWCs in Group I. However, neither tumor size nor operation time 
were identified as independent predictor for MWC development in the current study. 
Histological subtype differed between the groups, with significantly more low grade 
tumors in Group I. Since 20 of the myxoid liposarcomas (90.9%) included in Group I 
were low grade sarcomas, the larger proportion of myxoid liposarcomas in Group I 
might account for the difference in histological subtype as well as for the difference 
in tumor grade between the groups. The prediction model for MWC development 
should be interpreted with caution, the relative small sample size and low amount 
of events, 37 MWCs in total, influence the predictive value and the AUC for the ROC-
curve of the model. However, the model identified preoperative EBRT as significant 
predictor for MWC development, although some residual confounding might be 
present. The fact that elderly patients, or patients who underwent delayed wound 
closure tend to have a higher MWC risk seems reasonable. We cannot explain the 
association between R0-resections and the increased MWC risk. Possibly, bias plays 
a role, where preoperatively irradiated patients have an increased MWC risk but also 
a higher chance to undergo a R0-resection38, but we could not show a difference in 
margin status in our series.
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STS management and outcome can be improved by further centralization of sarcoma 
treatment.3,39 The multidisciplinary evaluation of patient- and tumor characteristics, 
as well as expected short- and long-term treatment-induced morbidity prior to the 
start of treatment results in an individualized approach.40 Furthermore this dedicated 
sarcoma treatment might facilitate a more liberal and consequent use of primary re-
constructive surgery which might lower the MWC risk in preoperative irradiated pa-
tients.26,41,42 Hence, in patients who underwent flap reconstruction, preoperative EBRT 
was not associated with MWC development.43 Moreover, early involvement of the 
plastic surgeon might enable the radiation oncologist to spare skin and soft tissue, i.e. 
consider them as ‘organ at risk’, which are planned to be used for the plastic surgical 
reconstruction. 
Further studies considering the ‘protective’ influence of primary reconstructive sur-
gery as well as studies comparing hypofractionated EBRT with conventionally frac-
tionated EBRT are necessary.44 
Conclusions
This study corroborates the increased MWC risk following preoperative radiotherapy 
and LSS when compared with postoperative radiotherapy and LSS in ESTS. Therefore, 
it remains important to carefully weigh the MWC risk against the expected long-term 
functional outcome, and to consider the liberal use of primary plastic surgical recon-
structions in an individualized multidisciplinary tumor board prior to ESTS treatment. 
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This feasibility study presents the results of a new intensive treat-
ment regimen for locally advanced extremity soft tissue sarco-
mas (ESTS), consisting of hyperthermic isolated limb perfusion 
(HILP), preoperative external beam radiotherapy (EBRT) and sur-
gical resection.
Methods
From 2011 to 2016, 11 high grade locally advanced ESTS patients 
underwent this treatment regimen. Preoperative EBRT (12x3 Gy) 
started <4 weeks following the HILP (TNF-α and melphalan) and 
the surgical resection was planned to take place <2 weeks fol-
lowing the end of the EBRT. 
Results
All patients completed the treatment. After a median follow-up 
of 32 (23-50) months, the limb was saved in 10 patients (91%), 
1 patient (9%) developed a local recurrence, 5 patients (45%) 
developed distant metastases and 3 patients (27%) died of 
their disease. During follow-up two patients (18%) developed a 
pathologic fracture of the treated limb and three patients (27%) 
developed a major wound complication requiring surgical inter-
vention. The median overall treatment time (OTT) was 56 (49-69) 
days. 
Conclusions
This intensive treatment regimen is feasible and safe in locally 
advanced ESTS, and it achieves oncological results that are com-
parable with conventional HILP treatment. In addition, the major 
wound complication risk is comparable and the OTT is reduced.
Introduction
Annually, approximately 600-700 patients are diagnosed with soft tissue sarcoma 
(STS) in The Netherlands, making it a relatively rare malignancy which accounts for 
less than 1% of all cancers in adults.1 
In patients with extremity soft tissue sarcoma (ESTS), amputation does not improve 
survival rates.2 Thus limb salvage treatment has become increasingly important over 
the years3 and neoadjuvant treatment regimens have been developed to prevent 
limb amputation in locally advanced ESTS. In the 1990s, there was renewed interest 
in hyperthermic isolated limb perfusion (HILP), originally developed by Creech et al. 
in 1957,4 for treating locally advanced ESTS.5-7 Initially, interferon-γ (IFN) and tumor 
necrosis factor-α (TNF-α) were added to the commonly used melphalan perfusate. 
However, IFN was soon abandoned due to ineffectiveness.8,9 The addition of TNF-α 
however, led to high response rates and limb preservation,8,9 and eventually to the 
approval of TNF-α in Europe,10 resulting in over 40 centers using HILP in the treatment 
of locally advanced ESTS.11
Since 1991, patients with locally advanced ESTS have been treated at the University 
Medical Center Groningen (UMCG) with neoadjuvant HILP followed by delayed surgi-
cal resection, and postoperative external beam radiotherapy (EBRT) when indicated. 
Hoven-Gondrie et al. described this cohort of 113 patients, of which 63 patients (56%) 
underwent HILP, surgery, and postoperative EBRT and 50 patients (44%) underwent 
HILP and surgery alone.12 This conventional perfusion treatment is extensive, long last-
ing, and the recovery and waiting time between the different treatment stages is long 
(six to eight weeks between neoadjuvant HILP and surgical resection and another six 
to eight weeks between surgical resection and the start of the postoperative EBRT, re-
sulting in an overall median treatment time of 22 (20-24) weeks (including the postop-
erative EBRT). Due to the postoperative timing of the EBRT, radiation schemes are long 
and high doses are administered i.e. 30-35x2 Gy. A follow-up study performed at the 
UMCG showed serious long-term treatment induced morbidity in 63% of patients.13 
Moreover, the long-term morbidity tends to be higher in postoperative irradiated pa-
tient as compared with preoperative EBRT in ESTS.14 
The standard preoperative EBRT dose for ESTS is 50 Gy given in 25 daily fractions of 2 
Gy, however, several studies have been conducted combining preoperative hypofrac-
tionated EBRT with neoadjuvant chemotherapy.15 
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At the UMCG a new intensive treatment regimen consisting of Perfusion, hypofrac-
tionated preoperative Radiotherapy and Surgery (PRS) for locally advanced ESTS was 
investigated with the ultimate goal to reduce the short- and long-term treatment-
induced morbidity and to reduce the overall treatment time (OTT) while achieving 
comparable oncological outcome. The results of this treatment regimen are present-
ed in this feasibility study. 
Materials and methods
Patients
From 2011 to 2016, 11 patients, nine males and two females with a median age of 64 
(44-74) years were included in this novel, Institutional Review Board (IRB) approved, 
treatment regimen (IRB protocol review case-number 2010.299). Patients diagnosed 
with a primarily non-resectable (locally advanced), non-metastatic, high grade ESTS 
were included in this study. At the UMCG all sarcoma patients are presented and dis-
cussed in a weekly multidisciplinary sarcoma team meeting. Accordingly, patients 
eligible for HILP treatment were included in the PRS treatment regimen based on 
a tumor board decision. Data were prospectively collected and retrospectively ana-
lyzed. The PRS treatment consisted of neoadjuvant HILP, preoperative hypofraction-
ated EBRT, followed by surgical resection with plastic surgical reconstruction when 
required. All patients were treated by a rehabilitation specialist and/or physiotherapist 
prior to, during, and after the treatment course, to optimize the functional treatment 
outcome. Follow-up ended at death or April 30, 2017. Data concerning demographics, 
tumor characteristics, comorbidity, hospitalization and follow-up were collected from 
medical records. The OTT was defined as the time between HILP and surgical resec-
tion and was used as marker to estimate the extent of treatment. 
Perfusion
The HILP procedure at the UMCG is based on the procedure developed by Creech et 
al.4 The operation was performed under general anesthesia. An incision was made, 
and the major artery and vein of the leg were isolated, collateral vessels ligated, and 
3.3 mg heparin per kg bodyweight was given intravenously. The blood flow of the leg 
was isolated from the systemic circulation by cannulating the main artery and vein 
and connecting it to an extracorporeal circuit. Subsequently, a tourniquet was ap-
plied to minimize leakage of TNF-α (Beromun®, Boehringer-Ingelheim GmbH, Vienna, 
Austria) and/or melphalan (Alkeran®, GlaxoSmithKline Pharmaceuticals, Research Tri-
angle Park, NC, USA) into the systemic circulation. A precordial scintillation detector 
and I131-human serum albumin were used to continuously measure the leakage into 
the systemic circulation.16,17 The ILP was performed under controlled mild hyperther-
mia (38.5-40.0˚C). For upper extremity and popliteal perfusions, 1 mg TNF-α was used; 
while, 2 mg was used for iliac or femoral perfusions. After 15 min of TNF-α perfusion, 
melphalan (10 mg/L limb volume for upper extremity and popliteal perfusions and 13 
mg/L for iliac and femoral perfusions) was added. After another 45 min, the limb was 
washed with 2 L (for upper extremity and popliteal perfusions) or 6 L (iliac/femoral) of 
saline. Afterwards, the limb was filled with red blood cell concentrate (1 U). The cannu-
las were removed, the vessels repaired, and the heparin antagonized with protamine 
sulphate. To prevent a compartment syndrome, a closed fasciotomy of the anterior 
compartment of the lower leg was performed.18,19 The patient was closely observed 
in the intensive care unit for the first 24 hours following the procedure. The complete 
perfusion technique and leakage monitoring have been previously described in more 
detail.20 
Radiotherapy
To complete the neoadjuvant therapy, patients were treated with preoperative hypof-
ractioned PET-CT guided EBRT, which was planned to start 4 weeks after HILP. Patients 
underwent an FDG PET-CT in radiation position to delineate the tumor, and to obtain 
gross tumor and planning target volumes (Figure 1). Intensity modulated radiotherapy 
was delivered with a linear accelerator in a hypofractionated schedule of 12x3 Gy. 
Figure 1. Delineation of a soft tissue sarcoma of the knee. In green the gross tumor volume and in 
red the planning target volume. On the left: a MRI scan fused to the radiotherapy planning CT-scan 
is shown, while on the right the FDG PET-CT scan is used for the delineation. 
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Resection 
After completion of the preoperative EBRT, the surgical resection was scheduled to 
take place within 2 weeks. Since only patients with locally advanced ESTS were in-
cluded, extensive surgical resections were performed. To achieve wound closure, plas-
tic surgical reconstructions were performed when required. Excision was classified as 
R0 when the resection margins were microscopically free of tumor cells, as R1 when 
resection margins were involved microscopically, and as R2 when resection margins 
were macroscopically comprised.21 Complications that occurred during treatment or 
within 120 days following the surgical resection were noted and classified according 
to Clavien-Dindo.22 Wound complications requiring surgical intervention were defined 
as major wound complication.
Histopathologic examination
Prior to treatment, a core needle biopsy was performed for histopathologic typing 
and grading of the tumor.23,24 All pathologic specimens were re-evaluated in 2017 by 
a pathologist with expertise in STS. The histopathologic tumor response to neoadju-
vant treatment was determined following recently published European Organization 
for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-
STBSG) recommendations.25 As follows: Grade A, no stainable tumor cells left; Grade 
B, single stainable tumor cells or small clusters (overall <1% left); Grade C, ≥1% - 10% 
stainable tumor cells left; Grade D, ≥10% - <50% stainable tumor cells left; and Grade 
E, ≥50% stainable tumor cells left. 
Statistical analysis
All variables were summarized with frequencies and percentages for discrete variables 
and medians and interquartile ranges (IQRs) for continuous variables; none of the vari-
ables were normally distributed. SPSS Version 22.0 (IBM SPSS Statistics for Windows, 
Version 22.0 Armonk, NY: IBM Corp) was used for statistical analyses. 
Results
All 11 patients, 9 males (82%) and 2 females (18%) with a median age 64 (44-74) years 
completed the scheduled PRS treatment regimen and all tumors were resectable fol-
lowing the neoadjuvant HILP and preoperative EBRT (Table 1). All tumors were high 
grade. Due to vascular involvement, one patient (9.1%) needed a vascular reconstruc-
tion following the surgical resection of the tumor remnant. Direct plastic surgical re-
constructions were performed in three patients (27%) to obtain wound closure. Histo-
pathologic examination of the resected specimens showed six R0 (55%), four R1 (36%) 
and one R2 resections (9%). The neoadjuvant treatment-induced tumor responses 
were: one grade A (9%), one grade B (9%), two grade C (18%), five grade D (45%), and 
two grade E (18%). 
A total of 14 complications (either medical or surgical) occurred in 10 patients following 
the PRS treatment (Table 2). Three patients (27%) developed a major wound complica-
tion (requiring surgical intervention), caused by necrosis or ischemia of the wound or 
surgical flap reconstruction. In one of these patients a lower limb amputation had to 
be performed due to ischemia causing an on-going secondary infection of the plastic 
surgery reconstruction. The median OTT for the PRS patients was 56 (49-69) days.
After a median follow-up of 32 (23-50) months, limb salvage was achieved in 10 patients 
(91%). One patient (9%) developed a local recurrence, five patients (45%) developed 
distant metastasis and three patients (27%) died of their disease. At end of follow-up 
six patients (55%) were alive without evidence of disease and two patients (18%) were 
alive with disease (Table 3). During follow-up, two pathologic fractures (18%) of the 
treated limb occurred: a femoral and a tibia compound fracture. The femoral fracture 
was treated by intramedullary fixation (Figure 2), and the tibia compound fracture was 
treated conservatively. 
Discussion 
The current study shows that the combination of neoadjuvant HILP and preopera-
tive EBRT is feasible in locally advanced ESTS. Over the past decades the limb saving 
treatment for locally advanced ESTS has evolved greatly, and new treatment strategies 
in ESTS treatment have been developed with the goal to improve outcome and/or 
to decrease morbidity. First, the addition of postoperative EBRT to HILP and delayed 
surgical resection resulted in a significant improvement in local control without in-
creasing morbidity in ESTS patients.26,27 Moreover, a follow-up study showed that dose 
reduction and a shorter HILP duration was safe and effective for patient outcome, as 
the 5-year local control rates and (limb) survival were not compromised.28 
HILP followed by delayed surgical resection and postoperative EBRT when indicated 
is commonly used and accepted throughout Europe to achieve local tumor control 
and limb salvage in locally advanced ESTS.11 This results in a limb salvage rate of ap-
proximately 80-90% in patients who would otherwise be considered for amputa-
tion.8,9,12,29-32 A systematic review by Bhangu et al.29 reported a limb salvage rate of 81%, 
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local recurrence rate of 27%, distant failure rate of 40% and a median 5-year disease 
specific survival ranging from 47-56% following HILP for ESTS.29 
The oncological outcome for patients following the PRS treatment regimen i.e. limb 
salvage rate of 91%, local recurrence rate of 9%, distant failure rate of 45% and disease-
specific survival of 73% seems to be comparable with the oncological outcome as 
reported in the literature.8,9,12,29-32
The subtle higher limb salvage rate in the current study might be due to the relatively 
short follow-up. This might also account for the lower local recurrence rate and higher 
disease specific survival rate in the current study. However, the difference in local re-
currence rate might also be caused by the consequent use of preoperative EBRT in 
the current series. Postoperative EBRT following HILP and delayed surgical resection 
was shown to improve the local tumor control in locally advanced ESTS, whereas the 
timing of EBRT does not seem to influence the oncological outcome in resectable 
ESTS.33-36 The distant failure rate in the current series (45%) seems similar to the 40% 
previously reported.29 However, due to the small sample size and relative short follow-
Table 1. Patient and tumor characteristics
Patient Gender Age Histopathologic findings Location Tumor size
1 M 32 Synovial sarcoma Upper leg 6
2 F 41 Synovial sarcoma Lower leg 4
3 F 74 Pleomorphic undifferentiated sarcoma Upper leg 10
4 M 54 Pleomorphic undifferentiated sarcoma Upper leg 17
5 M 63 Pleomorphic undifferentiated sarcoma Lower leg 9
6 M 71 Myxofibrosarcoma Upper leg 5
7 M 44 Myxofibrosarcoma Upper leg 17
8 M 74 Pleomorphic undifferentiated sarcoma Knee 7
9 M 64 Leiomyosarcoma Knee 6
10 M 75 Pleomorphic undifferentiated sarcoma Lower leg 8
11 M 67 Leiomyosarcoma Knee 6
Age at start of treatment (years). Tumor size; maximum diameter (cm) at preoperative MRI-scan. 
up, the current results should be interpreted with some caution and they need further 
confirmation in larger patient-cohorts.
The major wound complication risk found in the current study seems to be compa-
rable with earlier reported data, which showed that 26% of patients required re-op-
eration, re-intervention or deep wound packing due to a wound complication, after 
surgical resection following isolated limb perfusion.31 The subtle higher percentage in 
the current study might be related to the intensified and shortened treatment course, 
whereas the administration of EBRT in the preoperative setting in the PRS treatment 
regimen might also play a role.33 




grade according  
to Clavien-Dindo22
Total amount of complications n=14 I-IIIb
Medical 3 (21%)
•	 Urinary tract infection 1 II
•	 Urinary retention 2 I
Surgical 11 (79%)
•	 Seroma 2 I
•	 Rash following melphalan administration 1 I
•	 Wound infection needing intravenous antibiotics 1 II
•	 Deep venous thrombosis 1 II
•	 Cellulitis needing intravenous antibiotics 3 II
•	 Wound infection 1 IIIb
•	 Partial flap loss 2 IIIb
Patients developing a complication 10 (91%)
Patients developing a major wound complication 3 (27%)
Major wound complication: wound complication occurring during treatment or <120 days of surgi-
cal resection requiring surgical intervention. Abbreviation: PRS=perfusion, preoperative radiotherapy 
and surgery.
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Due to tumor heterogeneity in STS, tumor necrosis present prior to the start of treat-
ment cannot be distinguished from tumor necrosis induced by neoadjuvant treat-
ment, possibly leading to an overestimation of the effect of neoadjuvant treatment. 
Therefore, the effectiveness of neoadjuvant treatment, based on tumor necrosis, re-
ported in previous studies, including UMCG HILP series, might be questioned and tu-
mor necrosis should not be used when making treatment decisions.25,37 Moreover, the 
tumor response can differ throughout these heterogeneous tumors while the tumor 
response at the closest surgical margin might have the most predictive value for local 
recurrence. In 2016, this led to a proposal for the standardization of the histopatho-
logic examination of STS by the EORTC-STBSG. This protocol included a STS response 
score in which the tumor response to neoadjuvant treatment is estimated according 
to the proportion of stainable tumor cells.25 A recent study did not find an associa-
tion between the STS response score and survival following preoperative EBRT and 
Table 3. Treatment results and oncological outcome





1 C R0 No No Alive without disease
2 D R0 No Yes Died of disease
3 D R0 No No Alive without disease
4 D R1 No Yes Died of disease
5 A R0 Yes Yes Died of disease
6 E R1 No No Alive without disease
7 D R0 No Yes Alive with disease
8 B R0 No No Alive without disease
9 D R1 No Yes Alive with disease
10 E R1 No No Alive without disease
11 C R2 No No Alive without disease
*Histopathologic response Grade A, no stainable tumor cells left; Grade B, single stainable tumor 
cells or small clusters (overall <1% left); Grade C, ≥1% - 10% stainable tumor cells left; Grade D, ≥10% 
- <50% stainable tumor cells left; and Grade E, ≥50% stainable tumor cells left.25 #R-status.21 surgical resection.38 However, further studies considering local control and survival 
are necessary.
Postoperative EBRT in ESTS is characterized by long treatment times and high doses 
of radiotherapy resulting in increased long-term morbidity when compared with pre-
operative EBRT.14,15,33,35 Furthermore, the conventional HILP treatment is extensive, long 
lasting and includes long waiting periods between the different treatment stages (i.e. 
6-8 weeks between the HILP and surgical resection, and another 6-8 weeks between the 
surgical resection and the start of postoperative EBRT). Despite the higher major wound 
complication risk incorporated with preoperative EBRT, a tendency towards the use of 
preoperative EBRT seems to have originated in the treatment of resectable ESTS. 
As mentioned, the standard preoperative EBRT dose in ESTS treatment is 50 Gy in 25 
daily fractions of 2 Gy nowadays.15 In the past various preoperative hypofractionated 
EBRT regimens, 10x3.5 Gy, 10x3 Gy, 5x3.5 Gy and 8x3.5 Gy, combined with neoadjuvant 
chemotherapy have been conducted and resulted in acceptable local control rates.39-43
Recently, the oncological outcome in resectable ESTS and trunk STS following 5x5 
Gy hypofractionated preoperative EBRT was found to be comparable with the onco-
Figure 2. Pathologic femoral fracture treated by intramedullary fixation.
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logical outcome following the commonly used 25x2 Gy regimen. Furthermore, only 
7% of the patients in the 5x5 Gy study developed a wound complication requiring a 
surgical intervention.44 Dose reduction and hypofractionation in localized myxoid li-
posarcomas is under ongoing investigation and the first results of the DOREMY-study 
(NCT02106312) are awaited. These new hypofractionated preoperative EBRT schemes 
might lead to a further reduction in wound complication risk. 
In summary, the results of the current study indicate that combining HILP and preop-
erative hypofractionated EBRT as neoadjuvant treatment is feasible and might further 
improve the treatment of patients with locally advanced ESTS without increasing the 
risk of local failure. 
Conclusion
This study demonstrates that the intensive PRS treatment regimen is feasible and safe 
in locally advanced ESTS. The PRS treatment which combines neoadjuvant HILP and 
preoperative EBRT, achieves oncological results that are comparable with oncological 
outcome from earlier reported data. In addition, the major wound complication risk is 
comparable and the overall treatment time is reduced. 
References
1. Soft tissue sarcoma incidence, Neder-
landse kankerregistratie, beheerd door 
IKNL © [July] 2017. Available at: www.
cijfersoverkanker.nl.
2. Rosenberg SA, Tepper J, Glatstein E, 
et al. The treatment of soft-tissue sar-
comas of the extremities: Prospective 
randomized evaluations of (1) limb-
sparing surgery plus radiation therapy 
compared with amputation and (2) the 
role of adjuvant chemotherapy. Ann 
Surg. 1982;196(3):305-315.
3. Hoekstra HJ, Schraffordt Koops H, Old-
hoff J. Soft tissue sarcoma of the extre-
mity. Eur J Surg Oncol. 1994;20(1):3-6.
4. Creech O,Jr, Krementz ET, Ryan RF, 
Winblad JN. Chemotherapy of cancer: 
Regional perfusion utilizing an extra-
corporeal circuit. Ann Surg. 1958;-
148(4):616-632.
5. Krementz ET, Carter RD, Sutherland CM, 
Hutton I. Chemotherapy of sarcomas 
of the limbs by regional perfusion. Ann 
Surg. 1977;185(5):555-564.
6. Lienard D, Ewalenko P, Delmotte JJ, 
Renard N, Lejeune FJ. High-dose recom-
binant tumor necrosis factor alpha in 
combination with interferon gamma 
and melphalan in isolation perfusion of 
the limbs for melanoma and sarcoma. J 
Clin Oncol. 1992;10(1):52-60.
7. Hoekstra HJ, Schraffordt Koops H, Mole-
naar WM, Oldhoff J. Results of isolated 
regional perfusion in the treatment of 
malignant soft tissue tumors of the ex-
tremities. Cancer. 1987;60(8):1703-1707.
8. Eggermont AM, Schraffordt Koops 
H, Lienard D, et al. Isolated limb per-
fusion with high-dose tumor necro-
sis factor-alpha in combination with 
interferon-gamma and melphalan for 
nonresectable extremity soft tissue sar-
comas: A multicenter trial. J Clin Oncol. 
1996;14(10):2653-2665.
9. Eggermont AM, Schraffordt Koops H, 
Klausner JM, et al. Isolated limb per-
fusion with tumor necrosis factor and 
melphalan for limb salvage in 186 pa-
tients with locally advanced soft tissue 
extremity sarcomas. the cumulative 
multicenter European experience. Ann 
Surg. 1996;224(6):756-64.
10. European medicines agency 2014. 
Available at: www.ema.europe.eu.
11. Verhoef C, de Wilt JH, Grunhagen DJ, 
van Geel AN, ten Hagen TL, Egger-
mont AM. Isolated limb perfusion with 
melphalan and TNF-alpha in the treat-
ment of extremity sarcoma. Curr Treat 
Options Oncol. 2007;8(6):417-427.
12. Hoven-Gondrie ML, Bastiaannet E, van 
Ginkel RJ, Pras EB, Suurmeijer A, Hoeks-
tra HJ. Limb perfusion in soft tissue sar-
comas: Twenty years of experience. Ned 
Tijdschr Geneeskd. 2013;157(30):A6148.
13. Hoven-Gondrie ML, Thijssens KM, 
Geertzen JH, Pras E, van Ginkel RJ, 
Hoekstra HJ. Isolated limb perfusion 
and external beam radiotherapy for soft 
tissue sarcomas of the extremity: Long-
term effects on normal tissue according 
to the LENT-SOMA scoring system. Ann 
Surg Oncol. 2008;15(5):1502-1510.
3. A new limb saving treatment strategy for locally advanced sarcomas
58 59
14. Davis AM, O'Sullivan B, Turcotte R, et al. 
Late radiation morbidity following ran-
domization to preoperative versus pos-
toperative radiotherapy in extremity 
soft tissue sarcoma. Radiother Oncol. 
2005;75(1):48-53.
15. Haas RL, Miah AB, LePechoux C, et al. 
Preoperative radiotherapy for extre-
mity soft tissue sarcoma; past, pres-
ent and future perspectives on dose 
fractionation regimens and combined 
modality strategies. Radiother Oncol. 
2016;119(1):14-21.
16. van Ginkel RJ, Limburg PC, Piers DA, 
Schraffordt Koops H, Hoekstra HJ. Value 
of continuous leakage monitoring with 
radioactive iodine-131-labeled human 
serum albumin during hyperthermic 
isolated limb perfusion with tumor ne-
crosis factor-alpha and melphalan. Ann 
Surg Oncol. 2002;9(4):355-363.
17. Daryanani D, Komdeur R, Ter Veen J, 
Nijhuis PH, Piers DA, Hoekstra HJ. Conti-
nuous leakage measurement during 
hyperthermic isolated limb perfusion. 
Ann Surg Oncol. 2001;8(7):566-572.
18. Schraffordt Koops H, Oldhoff J, van der 
Ploeg E, Vermey A, Eibergen R, Beekhuis 
H. Some aspects of the treatment of 
primary malignant melanoma of the 
extremities by isolated regional perfu-
sion. Cancer. 1977;39(1):27-33.
19. Schraffordt Koops H. Prevention of neu-
ral and muscular lesions during hyper-
thermic regional perfusion. Surg Gyne-
col Obstet. 1972;135(3):401-403.
20. Hoekstra H. Isolated limb perfusion. 
In: Atlas of procedures in surgical on-
cology with critical, evidence-based 
commentary notes. RA Audisio: World 
Scientific Publishing Co, Pte, Ltd, Singa-
pore 596224; 2009:259-259-267.
21. Sobin L. Tumor of bone and soft tissues. 
R classification. In: Wittekind, CH edi-
tors. TNM Classification of malignant 
tumours, UICC, ed. 6th ed. New York: 
Wiley Liss; 2002:110.
22. Clavien PA, Barkun J, de Oliveira ML, et 
al. The clavien-dindo classification of 
surgical complications: Five-year expe-
rience. Ann Surg. 2009;250(2):187-196.
23. Edge SB, Byrd DR, Compton CC, Fritz 
AG, Green FL, Trotti A. AJCC cancer sta-
ging manual. 7th ed. Springer-Verlag 
New York; 2010.
24. Fletcher CDM, Bridge JA, Hogendoorn 
P, Mertens F. WHO classification of tu-
mours of soft tissue and bone. fourth 
edition. 150 Cours Albert Thomas, Lyon, 
France: IARC; 2013.
25. Wardelmann E, Haas RL, Bovee JV, et al. 
Evaluation of response after neoadju-
vant treatment in soft tissue sarcomas; 
the European organization for research 
and treatment of cancer-soft tissue and 
bone sarcoma group (EORTC-STBSG) 
recommendations for pathological exa-
mination and reporting. Eur J Cancer. 
2016;53:84-95.
26. Olieman AF, Pras E, van Ginkel RJ, Mole-
naar WM, Schraffordt Koops H, Hoekstra 
HJ. Feasibility and efficacy of external 
beam radiotherapy after hyperthermic 
isolated limb perfusion with TNF-alpha 
and melphalan for limb-saving treat-
ment in locally advanced extremity 
soft-tissue sarcoma. Int J Radiat Oncol 
Biol Phys. 1998;40(4):807-814.
27. Thijssens KM, van Ginkel RJ, Pras E, Suur-
meijer AJ, Hoekstra HJ. Isolated limb 
perfusion with tumor necrosis factor 
alpha and melphalan for locally ad-
vanced soft tissue sarcoma: The value of 
adjuvant radiotherapy. Ann Surg Oncol. 
2006;13(4):518-524.
28. Hoven-Gondrie ML, Bastiaannet E, van 
Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. 
TNF dose reduction and shortening of 
duration of isolated limb perfusion for 
locally advanced soft tissue sarcoma of 
the extremities is safe and effective in 
terms of long-term patient outcome. J 
Surg Oncol. 2011;103(7):648-655.
29. Bhangu A, Broom L, Nepogodiev D, 
Gourevitch D, Desai A. Outcomes of 
isolated limb perfusion in the treat-
ment of extremity soft tissue sarcoma: 
A systematic review. Eur J Surg Oncol. 
2013;39(4):311-319.
30. Deroose JP, Eggermont AM, van Geel AN, 
et al. Long-term results of tumor necrosis 
factor alpha- and melphalan-based iso-
lated limb perfusion in locally advanced 
extremity soft tissue sarcomas. J Clin 
Oncol. 2011;29(30):4036-4044.
31. Jakob J, Tunn PU, Hayes AJ, Pilz LR, No-
wak K, Hohenberger P. Oncological out-
come of primary non-metastatic soft 
tissue sarcoma treated by neoadjuvant 
isolated limb perfusion and tumor re-
section. J Surg Oncol. 2014;109(8):786-
790.
32. Grunhagen DJ, de Wilt JH, Graveland 
WJ, Verhoef C, van Geel AN, Eggermont 
AM. Outcome and prognostic factor 
analysis of 217 consecutive isolated 
limb perfusions with tumor necrosis 
factor-alpha and melphalan for limb-
threatening soft tissue sarcoma. Cancer. 
2006;106(8):1776-1784.
33. O'Sullivan B, Davis AM, Turcotte R, et 
al. Preoperative versus postoperative 
radiotherapy in soft-tissue sarcoma of 
the limbs: A randomised trial. Lancet. 
2002;359(9325):2235-2241.
34. Strander H, Turesson I, Cavallin-Stahl E. 
A systematic overview of radiation the-
rapy effects in soft tissue sarcomas. Acta 
Oncol. 2003;42(5-6):516-531.
35. Haas RL, Delaney TF, O'Sullivan B, et al. 
Radiotherapy for management of extre-
mity soft tissue sarcomas: Why, when, 
and where? Int J Radiat Oncol Biol Phys. 
2012;84(3):572-580.
36. Albertsmeier M, Rauch A, Roeder F, et 
al. External beam radiation therapy for 
resectable soft tissue sarcoma: A sys-
tematic review and meta-analysis. Ann 
Surg Oncol. 2018;25(3):754-767.
37. Vaynrub M, Taheri N, Ahlmann ER, et al. 
Prognostic value of necrosis after neo-
adjuvant therapy for soft tissue sarco-
ma. J Surg Oncol. 2015;111(2):152-157.
38. Schaefer IM, Hornick JL, Barysauskas CM, 
et al. Histologic appearance after preo-
perative radiation therapy for soft tissue 
sarcoma: Assessment of the European 
organization for research and treatment 
of cancer-soft tissue and bone sarcoma 
group response score. Int J Radiat On-
col Biol Phys. 2017;98(2):375-383.
39. Eilber F, Giuliano A, Huth JH. Neoad-
juvant chemotherapy, radiation, and 
limited surgery for high grade soft tis-
sue sarcomas of the extremity. In: Ryan 
JR BL, ed. Recent concepts in sarcoma 
treatment. Dordrecht, The Netherlands: 
Kluwer Academic Publishers; 1988:115-
116-122.
40. Hoekstra HJ, Schraffordt Koops H, Mo-
lenaar WM, et al. A combination of in-
traarterial chemotherapy, preoperative 
and postoperative radiotherapy, and 
surgery as limb-saving treatment of pri-
marily unresectable high-grade soft tis-
sue sarcomas of the extremities. Cancer. 
1989;63(1):59-62.
60
41. Eilber F, Eckardt J, Rosen G, Forscher C, 
Selch M, Fu YS. Preoperative therapy for 
soft tissue sarcoma. Hematol Oncol Clin 
North Am. 1995;9(4):817-823.
42. Nijhuis PH, Pras E, Sleijfer DT, Molenaar 
WM, Schraffordt Koops H, Hoekstra HJ. 
Long-term results of preoperative intra-
arterial doxorubicin combined with 
neoadjuvant radiotherapy, followed 
by extensive surgical resection for 
locally advanced soft tissue sarcomas 
of the extremities. Radiother Oncol. 
1999;51(1):15-19.
43. Temple WJ, Temple CL, Arthur K, Scha-
char NS, Paterson AH, Crabtree TS. Pros-
pective cohort study of neoadjuvant 
treatment in conservative surgery of 
soft tissue sarcomas. Ann Surg Oncol. 
1997;4(7):586-590.
44. Kosela-Paterczyk H, Szacht M, Mory-
sinski T, et al. Preoperative hypofractio-
nated radiotherapy in the treatment of 
localized soft tissue sarcomas. Eur J Surg 
Oncol. 2014;40(12):1641-1647. 








J Surg Oncol. 2018 Mar;117(3):434-442




Despite multimodality limb salvage treatment (LST) for locally 
advanced extremity soft tissue sarcoma (ESTS), some patients 
still need an amputation. Indications for amputation and onco-
logical outcome for these patients are described
Methods 
Between 1996 and 2016, all patients who underwent an amputa-
tion for ESTS were included. Patients who underwent an ampu-
tation as primary or as non-primary treatment formed Group I 
and II, respectively. 
Results
Thirty-nine patients were included, 16 in Group I (41%) and 23 in 
Group II (59%). Tumor size or local recurrence which could not 
be treated with LST were the two main reasons for amputation. 
Local recurrence free survival (LRFS) (p=0.396), distant metasta-
ses free survival (DMFS) (p=0.965), disease-specific survival (DSS) 
(p=0.745) and overall survival (OS) (p=0.718) were comparable 
for both groups. Ten-year LRFS was 90.0% vs. 83.7%; DMFS was 
31.0% vs. 42.2%; DSS was 52.2% vs. 44.1%; and OS was 44.2% vs. 
41.6%, for group I and II respectively. 
Conclusions
Oncological outcome seems to be comparable between pa-
tients who underwent a primary or a non-primary amputation 
for ESTS. With the on-going possibilities concerning prosthesis 
and rehabilitation programs, it remains important to decide in a 
multidisciplinary sarcoma team meeting which treatment suits 
best for each individual patient. 
Introduction
Soft tissue sarcomas (STS) are rare, malignant tumors with an incidence of 12 310 new 
cases in the United States and 729 in the Netherlands in 2016, resulting in 4 990/300 
STS related deaths in the United States and in the Netherlands in 2016.1-3 STS form a 
heterogeneous group of tumors including more than 50 different histologic subtypes. 
The most common subtypes are pleomorphic undifferentiated sarcoma (including 
malignant fibrous histiocytoma), liposarcoma, leiomyosarcoma, synovial sarcoma, and 
malignant peripheral nerve sheath tumor, which account for a total of 76% of all STS.4 
STS can occur at any anatomic location but most often arise in the limbs (60–70%).5-7 
Despite complete resection, with or without (neo)adjuvant treatment, STS are known 
for their potential to recur locally and/or to cause distant metastases, mainly to the 
lungs. The available data considering the improvement of survival following (neo)ad-
juvant systemic chemotherapy are inconsistent and under on-going investigation.8-10 
Amputation does not increase the survival rate of patients with extremity soft tis-
sue sarcoma (ESTS) when compared with limb salvage surgery combined with (post-
operative) radiotherapy. So, limb salvage treatment (LST) has been the treatment of 
choice since the early 1980s.11-13 The comparable survival of patients treated with either 
amputation or LST is caused by the similar effect of systemic chemotherapy in case 
of metastatic disease. Future identification of new systemic chemotherapy regimens 
might lead to an improvement of survival in these patients. 
Despite attempts to salvage the affected limb, some patients still require an amputa-
tion of the affected limb, even after successful hyperthermic isolated limb perfusion 
(HILP) or preoperative radiation therapy.14-16 Several patient-related factors (age, co-
morbidity) and tumor-related factors (tumor size, grade, proximity to vital structures) 
play a role in the decision to perform an amputation.5,6,14,17 
This study describes the indications and oncological outcome for patients who un-
derwent an amputation for ESTS at the University Medical Center Groningen (UMCG) 
between 1996 and 2016. 
Patients and methods
Patients
The Institutional Review Board (IRB) approved data collection by review of patient 
medical records (IRB case number 2016.675). All patients who underwent an amputa-
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tion for ESTS at the UMCG between January 1996 and January 2016, were included in 
this study. Patients were divided into two groups: those who underwent a primary 
amputation (Group I) and those who underwent an amputation as non-primary treat-
ment for ESTS (Group II). 
At the UMCG, all sarcoma patients are discussed in a multidisciplinary sarcoma team 
meeting prior to the start of treatment. This study retrospectively assessed all patients 
who underwent an amputation in the treatment of their ESTS. Including primary am-
putations, non-primary amputations, palliative amputations and amputations per-
formed for non-oncologic factors necessitating amputation during follow-up. 
To give insight in the indications for amputation among ESTS patients, the main rea-
son/or most attributable reason for amputation was formulated for each patient in 
this series. Amputation levels were preoperatively discussed in the multidisciplinary 
sarcoma team meeting and all patients were referred to a rehabilitation specialist for 
evaluation of the appropriate level of amputation. 
Data concerning demographics, tumor characteristics, patient treatment history, and 
hospitalization were collected from medical records. Demographic data included sex 
and age at diagnosis, type of amputation, and oncological outcome. (follow-up end-
ed at death or April 30, 2017). The tumor characteristics obtained from patient medical 
records included tumor size, tumor location, and histological subtype. 
Methods
Indications for amputation and data on each treatment modality (surgical and non-
surgical) were collected. Oncological outcome was measured by local recurrence free 
survival (LRFS) and distant metastases free survival (DMFS) after amputation. Further-
more, disease-specific survival (DSS) and overall survival (OS) were calculated from 
diagnosis till end of follow-up. 
Statistical analysis
Variables were summarized with frequencies and percentages for discrete variables 
and medians and interquartile ranges (IQRs) for continuous variables; none of the 
variables were normally distributed. The Mann–Whitney U test was used to compare 
demographics and clinical variables. Oncological outcome was calculated using the 
Kaplan–Meier method and Log-rank test. P values <0.05 were considered to indicate 
statistical significance. SPSS Version 22.0 (IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp) and GraphPad Prism version 5.00 for Windows (GraphPad Soft-
ware, San Diego California USA, www.graphpad.com) were used for statistical analysis.
Results
Patients and tumors
Patient demographics and tumor characteristics are presented in Table 1. A total of 
39 patients, median age 58.0 (52.0–69.0) years, 24 women (61.5%) and 15 (38.5%) men, 
were included in the study. A total of 16 patients (41%) underwent a primary amputa-
tion (Group I), and 23 patients (59%) underwent amputation as non-primary treat-
ment (Group II).
The overall median tumor diameter at diagnosis was 8.7 (4.7–13.0) cm, for Group I, 
11.5 (8.5–15.5) cm, and Group II, 6.1 (4.0–10.0) cm, (p=0.008). The most common tumor 
location was the upper leg (37.5%) for Group I, and the lower leg (34.8%) for Group II. 
A variety of histologic subtypes were seen, including pleomorphic undifferentiated 
sarcoma, liposarcoma (either myxoid, dedifferentiated, or pleomorphic), and synovial 
sarcoma (Table 1).
Amputations
There were 19 transfemoral amputations (48.7%), four transtibial amputations (10.3%), 
four transhumeral amputations (10.3%), two transradial amputations (5.1%), two inter-
scapulothoracic amputations (5.1%), three Syme’s amputations (7.7%), three hip disar-
ticulations (7.7%), one shoulder disarticulation (2.6%), and one partial hand amputa-
tion (2.6%) among the series. The median time between the primary diagnosis and 
the amputation was 17.0 (9.0–94.0) weeks, Group I, 8.5 (3.0–12.8) weeks, and Group II, 
80.0 (17.0–184.0) weeks (p<0.001). The technique of the various amputations and am-
putation levels is well described by Malawer and Sugarbaker.18 
As mentioned, the indications for amputation were discussed in the multidisciplinary 
sarcoma team meeting and the main reason/or most attributable reason for amputa-
tion was formulated to be able to classify the patients according to the indication for 
amputation. The treatment chosen for each individual patient depends on several 
patient and tumor characteristics. In Group I, a primary amputation was performed 
due to the non-resectability of the tumor caused by large tumor size in 8 patients 
(50%), in these patients it was estimated that the extent of surgical resection neces-
sary would have resulted in a non-functional limb. Therefore, a primary amputation 
was performed instead. In four patients (25%) an amputation was necessary due to 
bony involvement, these patients had (large) tumors with involvement of the bone in 
which no other treatment option was feasible. In two patients (12.5%) the involvement 
of the neurovascular bundle was the main reason for amputation. In the remaining 
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Male gender 15 (38.5) 7 (44.0) 8 (35.0) 0.740 
Age at diagnosis (years) 58.0 (52.0-69.0) 57 (52.3-67.5) 59 (41.0-70.0) 0.943
Tumor size (cm) 8.7 (4.7-13.0) 11.5 (8.2-15.5) 6.1 (4.0-10.0) 0.008
Histological subtype
•	 Liposarcoma 5 (12.8) 3 (18.8) 2 (8.7)
•	 MPNST 1 (2.6) 0 (0) 1 (4.3)
•	 Myxofibrosarcoma 3 (7.7) 1 (6.3) 2 (8.7)
•	 Synovial sarcoma 7 (17.9) 3 (18.8) 4 (17.4)
•	 Rabdomyosarcoma 2 (5.1) 1 (6.3) 1 (4.3)
•	 Angiosarcoma 1 (2.6) 1 (6.3) 0 (0)
•	 Pleomorphic  
undifferentiated sarcoma
10 (25.6) 5 (31.3) 5 (21.4)
•	 Radiation induced sarcoma 2 (5.1) 2 (12.5) 0 (0)
•	 Other 8 (20.5) 0 (0) 8 (34.8)
Tumor location 
•	 Upper leg 8 (20.5) 6 (37.5) 2 (8.7)
•	 Knee 5 (12.8) 1 (6.3) 4 (17.4)
•	 Lower leg 11 (28.2) 3 (18.8) 8 (34.8)
•	 Foot 5 (12.8) 2 (12.5) 3 (13.0)
•	 Upper arm 3 (7.7) 3 (18.8) 0 (0)
•	 Lower arm 6 (15.4) 1 (6.3) 5 (21.7)
•	 Hand 1 (2.6) 0 (0) 1 (4.3)
two patients (12.5%) limb salvage was not possible due to abscess formation within 
the tumor and secondary local infection, leading to an unsuited local environment for 
LST. The first patient suffered from a locally advanced STS of the upper leg. After the 
diagnostic biopsy the patient developed a tumor perforation through the skin and 
a secondary infection with abscess formation within the tumor. This infection dete-
riorated despite the administration of antibiotics. This local environment made the 
intended HILP irresponsible and a primary amputation was performed instead. The 
second patient had been suffering from a swollen and painful foot during an entire 
year prior to the presentation in our center. The patient had refused to seek medical 
help during that year. A soft tissue mass was diagnosed which was accompanied by 
a large abscess of the entire foot. The abscess was drained and a core-needle biopsy 
of the soft tissue mass was performed simultaneously. Histopathologic examination 
of the biopsy showed a synovial sarcoma. Due to the abscess formation his entire foot 
was destructed and a primary amputation was performed. Figure 1 shows four MR-









•	 Transfemoral 19 (48.7) 6 (37.5) 13 (56.5)
•	 Transtibial 4 (10.3) 2 (12.5) 2 (8.7)
•	 Transhumeral 4 (10.3) 1 (6.3) 3 (13.0)
•	 Transradial 2 (5.1) 0 (0) 2 (8.7)
•	 Interscapulothoracic 2 (5.1) 2 (12.5) 0 (0)
•	 Syme’s 3 (7.7) 1 (6.3) 2 (8.7)
•	 Hip disarticulation 3 (7.7) 3 (18.8) 0 (0)
•	 Shoulder disarticulation 1 (2.6) 1 (6.3) 0 (0)
•	 Partial hand 1 (2.6) 0 (0) 1 (4.3)
Data presented as n (%); median (IQR); Group I: Amputation as primary treatment; Group II: Am-
putation as non-primary treatment. Abbreviations: IQR=Inter Quartile Range; MPNST=Malignant 
Peripheral Nerve Sheath Tumor. 
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In Group I, one patient (6.3%) received 50 Gy preoperative external beam radiotherapy 
(EBRT) to facilitate a Syme’s amputation of the foot. Since the preoperative EBRT was 
given to ensure adequate margins for the primarily intended amputation, this patient 
was included in Group I. 
The 23 patients in Group II underwent several treatment modalities preceding the 
non-primary amputations. Fifteen patients (65.2%) underwent more than one treat-
ment modality preceding the amputation, and a total of 58 treatments, median 2 (1-4) 
Figure 1. MR-images showing four examples for non-resectable ESTS necessitating primary ampu-
tation. 
A Coronal image of a large ESTS of the right upper leg without involvement of the femur or the 
neurovascular structures. 
B Transversal image of an ESTS of the left upper leg with involvement of the neurovascular 
structures. 
C Sagittal image of an ESTS of the right foot with bony involvement. 
D Sagittal image of an ESTS of the left upper leg with skin perforation, abscess formation and sec-
ondary infection within the tumor (femur in black in this setting). 
treatments per patient were performed in Group II, as follows: 35 surgical resections, 
12 HILPs, two regimes of chemotherapy and nine EBRT regimes. 
In Group II, the indication to perform an amputation was a local recurrence, which could 
not be treated with LST in 12 patients (52.2%). Other indications to perform an amputa-
tion were: tumor progression and/or no tumor response to LST in four patients (17.4%), 
microscopically compromised margins after LST in three patients (13.0%), and ischemia 
and/or secondary infection of the treated limb in four patients (17.4%)(Table 2). 
A local recurrence which could not be treated with LST differs from tumor progression 
and/or no tumor response to LST. Hence, the patients who underwent an amputation 
because of a local recurrence which could not be treated with LST initially underwent 
successful LST. During follow-up they developed a local recurrence in which LST was 
not possible and therefore a non-primary amputation was performed. Whereas pa-
tients who suffered from tumor progression and/or no tumor response to limb sal-
vage treatment underwent an attempt for LST. This attempt for LST failed and the 
patients suffered from tumor progression during LST or their tumor did not respond 
to the LST. In these patients the unsuccessful attempt for LST necessitated a non-
primary amputation. 
Non-oncologic factors as ischemia and/or secondary infection of the treated limb ne-
cessitated a non-primary amputation during follow-up in four patients (17.4%). How-
ever, non-oncologic factors as intolerable pain, patient dissatisfaction with functional 
status or patients’ preference for amputation after initial LST were not found among 
the series. 
Follow-up
Median follow-up (time from diagnosis to end of follow-up) was 41.0 (16.0–155.0) months; 
Group I, 33.5 (11.5–79.8) months and Group II, 56.0 (16.0–176.0) months (p=0.207). No sig-
nificant differences in LRFS (p=0.396), DMFS (p=0.965), DSS (p=0.745) and OS (p=0.718) 
were found between both Groups (Figure 2). Ten-year LRFS was 90.0% vs. 83.7%; DMFS 
was 31.0% vs. 42.2%; DSS was 52.2% vs. 44.1%; and OS was 44.2% vs. 41.6%, for group I and 
II respectively. 
In Group I, one patient (6.3%) developed a local recurrence and eight patients (50.0%) 
developed distant metastasis during follow-up. Six patients received palliative treat-
ment for metastatic disease (one patient palliative EBRT and five patients palliative 
systemic treatment). For Group I, the median time of detection of a local recurrence or 
distant metastases was 13.0 (13.0-13.0) and 4.5 (1.3-17.0) months, respectively. 



































































































































































































































































































































































































































































































































































































































































































































































































































































4. Limb amputation: local control and survival
74 75
In Group II, four patients (17.4%) were diagnosed with distant metastases prior to the 
amputation, and a total of 13 patients (56.5%) developed distant metastases during 
follow-up after amputation. Four patients (17.4%) in Group II developed a local recur-
rence after amputation, of whom three were simultaneously diagnosed with distant 
disease. Six patients (26.1%) in Group II received palliative EBRT for metastatic disease, 
Figure 2. Kaplan-Meier plots showing no significant differences for: A Local recurrence free survival 
(p=0.396) and B Distant metastases free survival (p=0.965) after amputation; C Disease-specific sur-
vival (p=0.745) and D Overall survival (p=0.718) after diagnosis.
and a further two patients (8.7%) received palliative systemic therapy. For Group II, 
the median time of detection of a local recurrence or distant metastases was 18.5 (3.0-
59.5) and 6.0 (2.0-24.0) months, respectively. Among the series, one patient with wide-
spread metastases was lost to follow-up. Table 3 presents the follow-up characteristics 
of the time-period after diagnosis and after amputation.
As mentioned, in Group II four patients (17.4%) were diagnosed with distant metasta-
ses prior to amputation. However, not all four patients underwent a palliative amputa-
tion. Two patients had a inguinal lymph none-metastasis accompanying their primary 
tumor which were treated with curative-intent by a groin lymph node dissection in 
addition to the local LST. Both of these patients underwent a non-primary amputa-
tion during follow-up. The third patient had a local recurrence in his upper leg and the 
staging chest CT-scan showed lung metastases. After careful consideration and dis-
cussion in the multidisciplinary sarcoma team meeting the complaints of the local re-
currence justified the amputation. The fourth patient was diagnosed with a large sar-
coma of the upper leg. After initial surgical resection a local recurrence occurred and 
an intra-abdominal metastasis was diagnosed simultaneously. Regrettably, the initial 
surgical resection comprised the blood supply of the leg which resulted in ischemia 
and a secondary infection of the leg necessitating the non-primary amputation.
Currently, seven patients (43.8%) are alive in Group I, five with no evidence of disease 
and two with evidence of disease. In Group II, seven patients (30.4%) are still alive, six 
with no evidence of disease and one with evidence of disease. 
Discussion
Nowadays, (neo)-adjuvant treatment protocols (EBRT, HILP and/or chemotherapy) 
and surgery have made it possible to achieve a limb salvage rate of approximately 
80-90% for ESTS.13,19-23 However, in some cases a primary amputation is warranted for 
various reasons. 
This study describes two groups of high risk ESTS patients in whom an amputation 
was performed. Group I describes the characteristics of patients who underwent a 
primary amputation and Group II describes the patients in whom an attempt for LST 
was followed by a non-primary amputation during follow-up. The non-primary ampu-
tation followed after a median of 80.0 (17.0–184.0) weeks from diagnosis, and a median 
of 2 (1-4) treatments per patient. 
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Table 3. Follow-up after diagnosis and after amputation
Total series 
(n=39)
Group I  
(n=16)
Group II  
(n=23) p-value
Follow-up after diagnosis
Time between diagnosis and  
end of follow-up
41.0 (16.0-155.0) 33.5 (11.5-79.8) 56.0 (16.0-176.0) 0.207
Survival, patients alive at  
end of follow-up
14 (35.9) 7 (43.8) 7 (30.4)
Follow-up after amputation
Local recurrence, developed  
after amputation
5 (12.8) 1 (6.3) 4 (17.4) 
Median time of detection 13.0 (4.0-50.0) 13.0 (13.0-13.0) 18.5 (3.0-59.5)
Histological subtype
•	 Liposarcoma 1 (20.0) 0 (0) 1 (25.0)
•	 MPNST 1 (20.0) 0 (0) 1 (25.0)
•	 Radiation induced sarcoma 1 (20.0) 1 (100.0) 0 (0)
•	 Other 2 (40.0) 0 (0) 2 (50.0)
Treatment of local recurrence
•	 Curative re-resection +  
radiation therapy 1 (20.0) 0 (0) 1 (25.0)
•	 Curative re-amputation 2 (40.0) 0 (0) 2 (50.0)
•	 Palliative radiation therapy 1 (20.0) 1 (100) 0 (0)
•	 Palliative comfort care 1 (20.0) 0 (0) 1 (25.0)
Distant metastasis, developed 
after amputation 21 (53.8) 8 (50.0) 13 (56.5)
Median time of detection 6.0 (2.0-18.5) 4.5 (1.3-17.0) 6.0 (2.0-24.0)
Histological subtype
•	 Liposarcoma 3 (14.3) 1 (12.5) 2 (15.4)
•	 Myxofibrosarcoma 3 (14.3) 1 (12.5) 2 (15.4)
•	 Synovial sarcoma 2 (9.5) 1 (12.5) 1 (7.7)
•	 Rabdomyosarcoma 2 (9.5) 1 (12.5) 1 (7.7)
•	 Pleomorphic undifferenti-
ated sarcoma 5 (23.8) 2 (25.0) 3 (23.1)
•	 Radiation induced sarcoma 2 (9.5) 2 (25.0) 0 (0)
•	 Other 4 (19.0) 0 (0) 4 (30.8)
Data presented as n (%); median (IQR); time in months. Group I: Amputation as primary treat-
ment; Group II: Amputation as non-primary treatment. Abbreviations: IQR=Inter quartile range; 
MPNST=Malignant Peripheral Nerve Sheath Tumor.
The predominant indications for amputation in Group I, were tumor size and involve-
ment of bone and/or neurovascular structures. In these patients, an attempt for LST 
would have led to a non-functional limb. In Group II, the predominant indication for 
amputation was failure of the local/regional treatment, resulting in a local recurrence 
in which LST was no longer possible. The indications for primary and for non-primary 
amputation are consistent with earlier published data.6,14,17,24,25 
In a study by Stojadinovic et al., 1178 patients with localized primary STS of the extrem-
ity were identified and treated with limb salvage surgery.25 Of these patients, 204 (17%) 
developed local recurrence, of whom 18 were treated with a (non-primary) amputa-
tion whereas the remaining patients underwent another limb salvage surgery. Thirty-
four of this latter group were selected for a matched-pair analysis to compare out-
comes. Amputation was associated with an improvement in local control of disease 
(94% vs. 74%; p=0.04), but no significant difference in disease-free, disease-specific, or 
overall survival was found between the two groups.25 
In the current series it was shown that patients who underwent an attempt at LST, 
that ultimately resulted in a non-primary amputation, seem to have comparable on-
cological outcome when compared with patients who underwent a primary amputa-
tion. The DSS and OS rates might be lower than OS rates for STS in general (10-year 
survival of approximately 55%).26 However, it has to be taken into account that the 
patients in the UMCG series had initial ESTS with a poor prognosis, due to tumor size 
and/or histology. 
In Group II, prior to a non-primary amputation, 10 patients underwent a surgical re-
section as initial treatment of their ESTS. Seven of these 10 patients underwent their 
initial surgical resection at an outside institution (i.e. accidental marginal resection). Al-
though oncological outcome following an accidental marginal resection may be simi-
lar, these patients require wider resections.27,28 In the current series, all seven patients 
underwent a re-resection at our center and none of these patients had to undergo an 
amputation due to inadequate initial treatment. Most of these patients developed a 
local recurrence necessitating amputation during follow-up. 
In the current study, only one patient in Group I developed a local recurrence, in con-
trast to four local recurrences (17.4%) in Group II. Three patients out of these latter four 
were simultaneously diagnosed with distant metastases, so the clinical significance of 
these ‘local failures’ is questionable, e.g. expression of metastatic disease. Furthermore, 
the LRFS and DMFS were found to be comparable between the two Groups. 
Among the series, four patients (10.3%) were diagnosed with distant disease prior to 
the amputation. As mentioned, two of these patients were treated with curative-in-
tent while the other two patients underwent a palliative amputation. The median OS 
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following amputation was 5.5 months for these four patients and 1 month following 
the two palliative amputations performed. This poor median OS following palliative 
amputation seems to be comparable with the 6 months median OS recently reported 
by Smith et al.29 
The current study shows that patients who underwent a non-primary amputation un-
derwent 58 treatment modalities (median two treatments per patient) preceding the 
amputation. Although this figure of median two treatments modalities prior to the 
amputation in the 23 patients in Group II seems low, a previous study has shown that 
the psychological impact of regional tumor treatment (HILP in this study) is large, re-
sulting in post-traumatic stress syndrome in 20% of patients.30 In contrast, other stud-
ies did not show differences in quality of life and functional outcome when compar-
ing amputation with LST in the treatment of ESTS.31,32 Another study shows that 80% 
of the patients who underwent a non-primary amputation did not regret undergoing 
the initial attempt at LST.33
In the last decades, many options for prosthesis parts have entered the market, in-
cluding improved socket designs, technological advances such as microprocessor-
equipped prosthesis components (ankle and knee), and a wider choice in foot selec-
tion. A better prosthetic rehabilitation program also offers patients a better quality of 
life. Since the 1990s, osseointegration (Swedish) techniques, to ensure a stable fixation 
of the titanium implant into the bony tissue of the amputation stump, have evolved 
to become more standardized, too.34,35 With this technique, the human–prosthesis 
interface has been optimized, gait optimization has been achieved, and functional 
outcome has been improved. With the development of evidence-based guidelines, 
the amputee patient can have a standardized protocol for a rehabilitation program, 
which in the end leads to a better functional result.36-38 Considering the implications 
of ablative surgery, there are no data available comparing patients’ self-sufficiency af-
ter an upper vs. lower limb amputation is performed. However, it seems logical that 
lower limb amputations have a smaller impact on one’s daily routine than upper limb 
amputations do. Due to the fact that the upper limb harbors much more subtle tac-
tile functions and fine motor skills as the lower limb, prosthetic options after an up-
per limb amputation are less and the implications on the patients’ life are substantial. 
The finding that primary amputations were performed for larger and more proximally 
located ESTS might be caused by the fact that these tumors are diagnosed in a later 
stadium due to a naturally larger limb-circumference, i.e. limb volume, of the proxi-
mal limbs. Accordingly, ESTS of the distal limbs might be diagnosed earlier leading 
to more LST options since these tumors might be less extensive at time of diagnosis. 
Still, the development of a local recurrence or failure of the LST might result in a non-
primary amputation for some of these distal ESTS. 
This study has some limitations, the retrospective character of this study encompasses 
the risk of retrospective selection bias. However, this study includes all patients who 
underwent an amputation in the treatment of their ESTS, patients in Group I all had 
tumors necessitating a primary amputation. Whereas, patients in Group II had tumors 
in which an initial (or several) attempt for LST was considered to be possible. Fur-
thermore, it was chosen to exclude tumor grade from this manuscript, since almost 
one-third of data considering tumor grades was missing. Due to the retrospective 
nature of this study it was impossible to retrieve the tumor grade for these 12 patients. 
Whereas, the remaining 27 patients all suffered from a high grade (grade 2 or 3) ESTS. 
In summary, patients with ESTS for whom an amputation is indicated have a worse 
prognosis than patients with STS in general. However, patients who underwent a pri-
mary or a non-primary amputation for ESTS seem to have comparable oncological 
outcomes. Given this comparable oncological outcome, the need is urgent on behalf 
of the patient for amputation levels to be chosen adequately and for optimal rehabili-
tation to be provided by surgeons and rehabilitation specialists.39,40 
Conclusion
The timing of amputation does not seem to affect the oncological outcome of ESTS 
patients. Therefore LST remains the treatment of choice, even for locally advanced 
ESTS. Attempts to achieve local control with LST in patients with ESTS can result in 
multiple intensive treatments per patient. However, the time between diagnosis and 
amputation was significantly longer for Group II when compared with Group I (80.0 
(17.0–184.0 vs. 8.5 (3.0–12.8) weeks, p<0.001). Despite all efforts, some patients will need 
a non-primary amputation because of a local recurrence, failure of LST or LST-related 
complications. On-going possibilities are being realized in prosthesis and rehabilita-
tion programs, therefore it remains important to decide in a multidisciplinary fashion 
which treatment suits best for each individual patient. 
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Background
Soft tissue sarcomas (STS) are relatively rare malignancies, accounting for less than 1% 
of all cancers in adults. The number of patients presenting with STS each year is 600-
700 in the Netherlands, leading to approximately 300 STS related deaths annually.1,2
Roughly 50-60% of the STS arise in the extremities.3,4 At presentation, some of these 
extremity soft tissue sarcomas (ESTS) are considered non-resectable or ‘locally ad-
vanced’. Since the 1990s neoadjuvant hyperthermic isolated limb perfusion (HILP) has 
been used in Europe to prevent limb amputation in these patients,5 resulting in a 
limb salvage rate of 80-90% in locally advanced ESTS nowadays.6-9 HILP is used in all 
types of adult locally advanced ESTS. It allows to administer regional chemotherapy 
in high doses, as the affected limb is isolated from the systemic circulation during the 
procedure. Neoadjuvant systemic chemotherapy in ESTS is currently under ongoing 
investigation, as the data available considering patients' oncological outcome are in-
consistent.10-12
Fluorine-18-fluorodeoxyglucose positron emission tomography with computed to-
mography (18F-FDG PET-CT) scans have been used to evaluate tumor changes fol-
lowing HILP in locally advanced ESTS since the mid-1990s.13 Pretreatment maximum 
standardized uptake value (SUVmax), metabolically active tumor-volume (MATV) and 
total lesion glycolysis (TLG) were identified as significant predictors for overall survival 
in STS in a recent meta-analysis.14 Furthermore, post-treatment SUVmax was shown to 
be promising in monitoring treatment response. However, the identification of this 
latter parameter was solely based on two articles included in this meta-analysis. The 
first only included rhabdomyosarcomas, which is a chemosensitive sarcoma, and the 
second only included chest wall sarcomas.14-16 
The SUVmax of a lesion depends solely on the highest measured 18F-FDG uptake in 
one voxel, thereby making the measured SUVmax susceptible for noise.17 Further-
more, the question remains whether this one measurement is representative for large, 
heterogeneous tumors, as STS. In contrast, the SUVmax is the most robust parameter 
when comparing various software delineation programs, delineation methods and 
observers.18 The outcome of MATV and TLG parameters are much more dependent of 
the method of tumor delineation and the software program used for these analyses. 
We hypothesized that the use of peak standardized uptake value (SUVpeak) and mean 
standardized uptake value (SUVmean) in addition to SUVmax, TLG and MATV might 
Abstract
Background
This study explores various volume of interest (VOI) delineation 
techniques for fluorine-18-fluorodeoxyglucose positron emission 
tomography with computed tomography (18F-FDG PET-CT) scans 
during neoadjuvant extremity soft tissue sarcoma (ESTS) treatment.
Results
During neoadjuvant treatment, hyperthermic isolated limb perfu-
sion (HILP) and preoperative external beam radiotherapy (EBRT), 11 
patients underwent three 18F-FDG PET-CT scans. The first scan was 
made prior to the HILP, the second after the HILP but prior to the 
start of the EBRT and the third prior to surgical resection. An auto-
matically drawn VOIauto, a manually drawn VOIman, and two gradient-
based semi-automatically drawn VOIs (VOIgrad and VOIgrad+) were ob-
tained. Maximum standardized uptake value (SUVmax), SUVpeak, 
SUVmean, metabolically active tumor-volume (MATV) and total 
lesion glycolysis (TLG) were calculated from each VOI. The correla-
tion and level of agreement between VOI delineation techniques 
was explored. Lastly, the changes in metabolic tumor activity were 
related to the histopathologic response. The strongest correlation 
and an acceptable level of agreement was found between the VO-
Iman and the VOIgrad+ delineation techniques. A decline (VOIman) in 
SUVmax, SUVpeak, SUVmean, TLG and MATV (all p<0.05) was found 
between the three scans. A >75% decline in TLG between scan 1 
and scan 3 possibly identifies histopathologic response. 
Conclusions
The VOIgrad+ delineation technique was identified as most reliable 
considering reproducibility when compared with the other VOI 
delineation techniques during the multimodality neoadjuvant 
treatment of locally advanced ESTS. A significant decline in meta-
bolic tumor activity during the treatment was found. TLG deserves 
further exploration as predictor for histopathologic response after 
multimodality ESTS treatment. 
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Figure 1. Coronal 18F-FDG PET-CT images showing the heterogeneous 18F-FDG uptake throughout the 
tumor for one of the patients during the treatment course. 
A scan 1 (baseline)
B scan 2 (after HILP)
C scan 3 (after EBRT) 









1 M 32 Synovial sarcoma Upper leg 6
2 F 41 Synovial sarcoma Lower leg 4
3 F 74 Pleomorphic undifferentiated sarcoma Upper leg 10
4 M 54 Pleomorphic undifferentiated sarcoma Upper leg 17
5 M 63 Pleomorphic undifferentiated sarcoma Lower leg 9
6 M 71 Myxofibrosarcoma Upper leg 5
7 M 44 Myxofibrosarcoma Upper leg 17
8 M 74 Pleomorphic undifferentiated sarcoma Knee 7
9 M 64 Leiomyosarcoma Knee 6
10 M 75 Pleomorphic undifferentiated sarcoma Lower leg 8
11 M 67 Leiomyosarcoma Knee 6
result in a more reliable prediction of tumor changes induced by neoadjuvant treat-
ment. 
To the best of our knowledge the use of various VOI delineation techniques has not 
yet been explored in, and during the neoadjuvant treatment of STS. Furthermore, in 
this patient population no sequential analysis of multiple 18F-FDG PET-CT scans has 
been performed previously. In this feasibility study, consecutive 18F-FDG PET-CT scans 
per patient were used to investigate the use of four VOI delineation techniques be-
cause variations in VOI will directly affect the measured SUVmean, MATV and TLG and 
could thus affect the performance of the PET assessments. Furthermore, we explored 
the changes in metabolic tumor activity (SUVmax, SUVpeak, SUVmean, MATV and 
TLG) to neoadjuvant HILP and preoperative EBRT during the treatment course of lo-
cally advanced ESTS. Lastly, the relationship between changes in metabolic tumor 
activity and histopathologic response was explored.
Materials and methods
This study has been approved by the Institutional Review Board (IRB) and the need 
for written informed consent was waived (IRB case number 2016.984). From 2011 to 
2017, 11 patients with a median age of 64 (IQR 44-74; range 32-74) years were treated 
according to a novel treatment regimen consisting of neoadjuvant HILP, preoperative 
hypofractionated EBRT, followed by surgical resection of the tumor. All patients were 
diagnosed with a locally advanced, non-metastatic, high grade ESTS (Table 1). Patients 
eligible for HILP treatment were included in this novel treatment regimen based on 
a tumor board decision. Inclusion and exclusion criteria, as well as treatment details 
have been described in more detail elsewhere.19 Patients were scheduled for three 
18F-FDG PET-CT scans. The first scan was made prior to the start of neoadjuvant treat-
ment (baseline), the second after the HILP, but prior to the start of the preoperative 
EBRT and was additionally used for EBRT delineation. The third scan was made after 
completion of the neoadjuvant treatment (HILP and EBRT), but prior to surgical resec-
tion. Figure 1 illustrates the change in 18F-FDG uptake during the treatment course for 
one of the patients.
18F-FDG PET-CT
The 18F-FDG PET-CT scans were performed using a hybrid PET-CT scanner (Siemens 
Biograph mCT). Patients fasted at least six hours prior to scanning, and fasting glucose 
levels were checked at time of injection, none of the patients suffered from diabetes 
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plemental Methods. Changes in metabolic tumor activity during neoadjuvant treat-
ment were measured using the five metabolic parameters obtained from the refer-
ence VOIman and were related to histopathologic responses. Histopathologic tumor 
responses were established in accordance with the European Organization for Re-
search and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) 
STS response score.19 Grade A representing no stainable tumor cells; Grade B, single 
stainable tumor cells or small clusters (overall below 1% of the whole specimen); 
Grade C, ≥1%-<10% stainable tumor cells; Grade D, ≥10%-<50% stainable tumor cells; 
and Grade E, ≥50% stainable tumor cells.26 
Histopathologic responders had tumor remnants which showed <10% stainable cells, 
combining response grades A, B and C. Non-responders had ≥10% stainable cells in 
their tumor remnant, Grade D or E. Lastly, the relationship between changes in meta-
bolic tumor activity and histopathologic responses was explored. 
Statistical analysis
Discrete variables were summarized with frequencies and percentages, and continu-
ous variables with medians and interquartile ranges (IQRs); none of the variables were 
mellitus. 18F-FDG (3 MBq/kg) was injected and the PET-CT scan was started one hour 
afterwards. Patients were scanned in supine position and images of the affected limb 
were acquired in 3D mode, in 2 to 5 bed positions, 1-3 minutes/bed position based on 
the patient’s body weight. A preceding low dose CT scan was performed and used 
for attenuation and scatter correction. All images were reconstructed using an EARL 
compliant protocol, from 2011 to 2014 the images were reconstructed using the fol-
lowing reconstruction: 3i_24s; image size 400; filter: Gaussian; FWHM 5.0mm, and from 
2014 to 2017 the images were reconstructed with the following reconstruction pa-
rameters: 3i_21s; image size 256; filter: Gaussian; FWHM 6.5mm; quality ref mAS 30. All 
scans were acquired according to European Association of Nuclear Medicine guide-
lines (version 1.0/2.0).20,21 
Image analyses
Scans were imported into Accurate (in-house developed analysis software, as previ-
ously used by Frings and Kramer et al.22,23, and recently described by Boellaard.24 Scans 
were reviewed and analyzed by one researcher. To explore the effect of various de-
lineation techniques on the measurement of the metabolic parameters, the volume 
of interest (VOI) of each tumor was drawn in four different ways: (1) an automatically 
drawn VOIauto (using 50% of the SUVpeak contour, corrected for local background,
22 
(2) a manually drawn VOIman (visually following tumor contours), (3) a semi-automatic 
drawn VOIgrad (a contour that is located at the maximum PET image intensity gradient 
near the boundary of the tumor). Because of tumor heterogeneity, necrotic tumor 
parts (mostly tumor centers) were not included in this third VOI. Therefore a fourth VOI 
was derived from the VOIgrad, in which all necrotic tumor parts were manually filled 
and included, resulting in the fourth VOIgrad+ (Figure 2). 
Five metabolic parameters: SUVmax (voxel with the highest SUV value), SUVpeak (us-
ing a 1mL sphere), SUVmean, TLG (SUVmean x MATV) and MATV, all based on lean 
body mass, as recommended by Boellaard et al.21, were derived for the four VOI deline-
ation techniques. 
Due to tumor necrosis in most tumors, either treatment-induced or due to tumor het-
erogeneity, only the VOIman comprised the entire tumor (including necrosis). Therefore, 
the VOIman was chosen as reference measurement, and the other VOI techniques were 
compared with the VOIman. We selected VOIman as reference VOI for pragmatic reasons 
(as the VOIman encompasses the entire tumor), not suggesting that this approach is best. 
Correlation analyses, Bland-Altman analyses and patient ranking were performed to 
compare correlation and level of agreement between the VOI delineation techniques. 
Bland-Altman analyses25 and patient ranking are described in more detail in the Sup-
Figure 2. An example illustrating the differences in tumor delineation between the four VOI delinea-
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Table 2. Spearman’s correlation between the VOIman and VOIauto/grad/grad+ for the 
serial 18F-FDG PET-CT scans








•	 VOIman-auto 1.000 NA 1.000 NA 0.988 <0.001
•	 VOIman-grad 1.000 NA 1.000 NA 1.000 NA
•	 VOIman-grad+ 1.000 NA 1.000 NA 1.000 NA
SUVpeak
•	 VOIman-auto 1.000 NA 1.000 NA 0.988 <0.001
•	 VOIman-grad 1.000 NA 1.000 NA 1.000 NA
•	 VOIman-grad+ 1.000 NA 1.000 NA 1.000 NA
SUVmean
•	 VOIman-auto 0.964 <0.001 0.836 0.001 0.564 0.090
•	 VOIman-grad 0.991 <0.001 0.882 <0.001 0.758 0.011
•	 VOIman-grad+ 0.991 <0.001 0.982 <0.001 0.988 <0.001
TLG
•	 VOIman-auto 0.845 0.001 0.982 <0.001 0.842 0.002
•	 VOIman-grad 0.991 <0.001 1.000 NA 0.976 <0.001
•	 VOIman-grad+ 0.991 <0.001 0.991 <0.001 0.988 <0.001
MATV
•	 VOIman-auto 0.309 0.355 0.555 0.077 0.430 0.214
•	 VOIman-grad 0.955 <0.001 0.973 <0.001 0.806 0.005
•	 VOIman-grad+ 0.936 <0.001 1.000 NA 0.964 <0.001
Spearman’s test for correlations was used to calculate significance. The strongest correlation for the 
three PET scans was found between the VOIman and the VOIgrad+, as indicated in bold. Abbreviations: 
VOI=volume of interest; VOIman=manually drawn VOI; VOIauto=automatically drawn VOI; VOIgrad=VOI 
based on the gradient between voxels; VOIgrad+=VOIgrad + necrosis; 
18F-FDG PET-CT=Fluorine-18-fluoro-
deoxyglucose positron emission tomography with computed tomography; SUVmax=maximum 
standardized uptake value; SUVpeak=peak standardized uptake value; SUVmean=mean standard-
ized uptake value; TLG=total lesion glycolysis; MATV=metabolically active tumor-volume; IQR=inter 
quartile range; NA=not applicable. 
normally distributed. Fisher’s exact and Mann-Whitney U test were used to compare 
variables. Wilcoxon signed rank and Friedman’s test were used to compare the meas-
urements between the three scans. Correlation coefficients were calculated, and test-
ed using Spearman’s test. The level of agreement between VOI techniques was deter-
mined by Bland-Altman analyses.25 A p-value <0.05 indicated statistical significance. 
Microsoft Excel (2010) was used to create the Bland-Altman plots. SPSS version 23.0 
(IBM SPSS Statistics for Windows, Version 23.0 Armonk, NY: IBM Corp) and GraphPad 
Prism version 5.04 (GraphPad Software for Windows, San Diego California USA) were 
used for statistical analyses.
Results
Thirty-two 18F-FDG PET-CT scans were acquired. The third PET-CT scan of patient 10 
could not be performed due to scheduling difficulties. For patient 1, in scan 3 it was 
not possible to draw a VOIauto, since the tumor showed an almost complete metabolic 
response at this treatment stage and it did not meet the margin thresholds to com-
plete the VOIauto. Since it was possible to define the other three types of VOIs, this scan 
was included in the analyses and a value of zero was given to the metabolic param-
eters for the VOIauto. The median time between the HILP and scan 2 was 21 (18-21) days, 
whereas the time between the end of EBRT and scan 3 was 3 (1-3) days. 
Correlation, level of agreement and ranking of patients between VOIs
The correlation between VOIs for all scans and all metabolic parameters was strongest 
between the VOIman and the VOIgrad+, as indicated in bold in Table 2. The Bland-Altman 
plots showed an acceptable level of agreement between the VOIman and the VOIgrad+ 
(Supplemental Figure 1). 
No larger difference than 1 place in ranking for SUVmean and TLG for the serial 18F-
FDG PET-CT scans was found when comparing the VOIman and the VOIgrad+ delineation 
techniques, for the MATV no larger difference than 2 places in ranking was found. A 
relative large difference of 4 or more in ranking between VOI delineation techniques is 
indicated in bold in Supplemental Table 1. Among others this was found for the MATV 
at scan 1 of patient 7 with considerable necrotic tumor parts. The measured MATV was 
found to be highest when using the VOIman, grad and grad+ techniques. However when the 
VOIauto technique was used it was only ranked a 9




During neoadjuvant treatment all five metabolic parameters for the reference VOIman 
declined between scans 1-3 (all p<0.05, Figure 3, Table 3). 
This decline was further explored by calculating the absolute and the percentage 
difference between the three serial scans. The percentage difference was obtained 
by dividing the difference between scans by the measured value of the first scan. 
A significant decline in SUVmax, SUVpeak and SUVmean was found between scan 
1 vs. scan 2, as well as between scan 1 vs. scan 3. However, no significant decline in 
SUVmax, SUVpeak and SUVmean was found between scan 2 vs. scan 3. The decline in 
TLG was significant between all serial scans. A significant decline in MATV was found 
between scan 2 vs. scan 3. The decline in metabolic tumor activity for all parameters 
except MATV was largest between scan 1 vs. 2, whereas the decline in MATV was larg-
est between scan 2 vs. 3 (Figure 4, Table 4).
Supplemental Figure 1. Bland-Altman plots showing the level of agreement between the VO-
Iman and the VOIauto/grad/grad+ for the serial 
18F-FDG PET-CT scans for: A SUVmean; B total lesion glyco-
lysis (TLG); C metabolically active tumor-volume (MATV). 
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Supplemental table 1. Continued
Patient 
No. MATV scan 1

























1 10 5 10 11 10 9 10 10 9 10 10 10
2 11 6 11 9 11 8 11 11 10 5 7 8
3 3 1 2 3 2 2 2 2 2 3 3 2
4 2 2 3 2 3 7 3 3 3 9 2 3
5 8 11 7 7 9 10 9 9 7 6 6 7
6 9 7 9 10 6 3 5 6 5 2 4 5
7 1 9 1 1 1 1 1 1 1 1 1 1
8 6 10 5 5 4 11 6 4 4 8 8 4
9 4 4 6 6 7 4 7 7 6 4 5 6
10 5 3 4 4 5 5 4 5 N/A N/A N/A N/A
11 7 8 8 8 8 6 8 8 8 7 9 9
Rank 1 is given for the highest value, and rank 11 for the lowest value calculated for SUVmean, TLG 
and MATV for all scans. In bold: a difference of four or more between the highest and lowest rank. 
Abbreviations: VOI=volume of interest; VOIman=manually drawn VOI; VOIauto=automatically drawn 
VOI; VOIgrad=VOI based on the gradient between voxels; VOIgrad+=VOIgrad + necrosis; SUVmean=mean 
standardized uptake value; TLG=total lesion glycolysis; MATV=metabolically active tumor-volume; 
NA=not applicable. 
Supplemental table 1. Ranking of patients for SUVmean, TLG and MATV ac-
cording to the four VOI delineation techniques
Patient

























1 10 10 10 10 10 10 10 10 9 10 9 9
2 11 11 11 11 9 11 11 9 10 9 10 10
3 7 8 7 7 11 7 7 11 7 3 6 7
4 2 2 2 2 1 1 1 2 4 1 1 3
5 6 4 6 6 6 8 8 4 5 8 7 5
6 9 9 8 8 5 6 5 6 2 4 3 2
7 8 7 9 9 8 9 9 8 6 7 8 6
8 1 1 1 1 7 4 6 7 8 5 4 8
9 4 5 4 4 2 2 2 1 1 2 2 1
10 5 6 5 5 3 3 3 3 N/A N/A N/A N/A
11 3 3 3 3 4 5 4 5 3 6 5 4
Patient 
No. TLG scan 1

























1 10 10 10 10 10 10 10 10 9 10 10 10
2 11 11 11 11 11 11 11 11 10 9 9 9
3 3 2 3 3 3 3 3 3 3 4 3 3
4 1 1 1 1 2 2 2 2 2 5 2 2
5 8 9 8 8 9 9 9 9 7 6 6 7
6 9 8 9 9 6 6 6 7 5 3 5 5
7 2 7 2 2 1 1 1 1 1 1 1 1
8 4 3 4 4 7 8 7 6 6 8 7 6
9 5 5 6 6 5 4 5 5 4 2 4 4
10 6 4 5 5 4 5 4 4 N/A N/A N/A N/A
11 7 6 7 7 8 7 8 8 8 7 8 8
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Figure 3. The course in metabolic tu-
mor activity for the VOIman during the 
neoadjuvant treatment for each pa-





D Metabolically active tumor-volume 
(MATV)
E Total lesion glycolysis (TLG)
Histopathologic response
Histopathologic response to neoadjuvant treatment varied among the 11 patients, as 
follows: one grade A (9.1%), one grade B (9.1%), two grade C (18.2%) (totaling to four 
histopathologic responders (36.4%)), five grade D (45.5%), and two grade E (18.2%) 
(totaling to 7 non-responders (64.4%)). The histopathologic responders seem to be 
identifiable by a decline in TLG of >75% between scan 1 and 3 calculated using the 
VOIman (Table 5). 
To further explore the identification of the histopathologic responders, the differ-
ence and percentage difference in TLG between scan 1 and 3 for the four VOI deline-
ation techniques was calculated (Supplemental Table 2). A calculated decline in TLG 
of >75% using the VOIgrad/grad+, identified the same histopathologic responders as the 
VOIman. The VOIauto however failed to identify patient 5 as histopathologic responder. 
Furthermore, a >75% decline in TLG was also found with the VOIauto and VOIgrad in pa-
tients 3 and 4, and with the VOIgrad+ in patient 4.
Table 3. Metabolic tumor activity for the VOIman for the serial 
18F-FDG PET-CT 
scans 
Parameter Scan 1 Scan 2 Scan 3 p-value
SUVmax 6.5 (3.3-9.5) 2.8 (2.4-4.1) 2.7 (1.9-3.6) 0.002
SUVpeak 5.6 (2.8-8.5) 2.5 (1.9-3.4) 2.4 (1.6-3.0) 0.001
SUVmean 2.4 (1.7-3.7) 1.3 (1.0-2.0) 1.2 (1.0-1.7) 0.006
TLG 434.8 (108.6-1112.8) 159.9 (44.7-570.9) 137.5 (22.6-572.6) 0.003
MATV (ml) 124.4 (64.8-474.2) 98.3 (35.2-534.2) 87.1 (15.1-437.7) 0.025
Data presented as median (IQR). Abbreviations: VOI=volume of interest; VOIman=manually drawn 
VOI; 18F-FDG PET-CT=Fluorine-18-fluorodeoxyglucose positron emission tomography with com-
puted tomography; SUVmax=maximum standardized uptake value; SUVpeak=peak stand-
ardized uptake value; SUVmean=mean standardized uptake value; TLG=total lesion glycolysis; 
MATV=metabolically active tumor-volume; IQR=inter quartile range. 
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Figure 4. Changes in metabolic tumor 
activity for the VOIman during the neoadju-
vant treatment for the serial 18F-FDG PET-





D Metabolically active tumor-volume 
(MATV)
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Discussion
This study studying four VOI delineation techniques in three consecutive 18F-FDG PET-
CT scans per patient demonstrates a significant decline in metabolic tumor activity 
(VOIman) during the neoadjuvant treatment, consisting of HILP and preoperative EBRT, 
of locally advanced ESTS. The decline in SUVmax, SUVpeak, SUVmean and TLG be-
tween scan 1 vs. 2 implies that the HILP accounts for the largest effect on metabolic 
tumor activity. The MATV seems to be affected most by the EBRT, given the significant 
decline found between scan 2 vs. 3. 
In search of a uniform and reproducible way to calculate changes in metabolic tumor 
activity in these upfront highly heterogeneous tumors, the use of four different VOI 
delineation techniques was studied. The VOIman (defined as reference VOI) is the only 
delineation technique in which the entire tumor is encompassed independently of 
the amount of necrosis present in the tumor. Therefore the VOIman delineation tech-
nique seems to be most reliable when used for calculating the metabolic tumor activ-
ity. However, the VOIman delineation technique is time-consuming, making it unfit for 
implementation into daily practice. A high correlation, acceptable level of agreement 
and comparable ranking was found between the VOIman and the VOIgrad+ delineation 
techniques. The differences in ranking between the four VOI delineation techniques 
are best explained by the high amount of necrosis present in these tumors, as tumor 
necrosis did not meet the margin thresholds of the VOIauto and VOIgrad. To obtain the 
VOIgrad+, the necrosis was manually included and therefore the ranking of patients was 
comparable to the ranking according to the VOIman. 
Thus, the VOIgrad+ delineation technique seems to be a reliable and reproducible tech-
nique for the delineation of heterogeneous tumors as ESTS. Further studies including 
larger patient-cohorts in various solid tumor types are necessary for the validation and 
reproducibility of the various VOI delineation techniques. This study, however, demon-
strates that the applied VOI delineation technique is important to consider because 
we found that assessment of response based on metabolic parameters derived from 
different VOIs may differ across subjects. 
The metabolic tumor changes during neoadjuvant treatment between scan 1 vs. scan 3 
were analyzed and compared with the corresponding histopathologic tumor response. 
Out of the five metabolic parameters tested, TLG seemed to identify the histopathologic 
responders most reliably (>75% decrease in TLG between scan 1 and scan 3) when using 
the VOIman delineation technique. Using the 75% decrease in TLG as a cut-off value was 
derived empirically from the data, used as example, and to obtain pilot data for using 
and comparing these techniques. When compared with the VOIman delineation tech-
nique, the VOIgrad+ technique identified the same histopathologic responders with only 
one additional patient. It seems that these two delineation techniques most reliably 
identify histopathologic responders, because they include tumor necrosis. The differ-
ence in performance of the VOIman and VOIgrad+ delineation techniques in identifying his-
topathologic responders is very subtle. However, the VOIgrad+ delineation technique was 
found to be easier in use and is considerably less time-consuming than the VOIman tech-
nique, making it more suitable for implementation into daily practice. The VOI delinea-
tion techniques and the TLG cut-off value need confirmation in larger patient-cohorts.
During the last years, the predictive value of 18F-FDG PET-CT scans in staging and mon-
itoring treatment response during neoadjuvant treatment has been established for 
various solid tumors (including metastatic colorectal cancer and non-small cell lung 
cancer. 23,27-29 Therefore, further ESTS studies in which metabolic tumor activity, e.g. 
>75% decrease in TLG with VOIman and/or VOIgrad+, is explored as predictor for monitor-
ing therapy response, for histopathologic findings and for oncological outcome are 
warranted. The identification of reproducible and reliable VOI delineation techniques, 
as well as the identification of robust PET parameters for the interpretation of changes 
in metabolic tumor activity is relevant because this will enable clinicians to shorten 
delineation time, and to compare results between observers, patients and centers for 
ESTS and for other solid tumor types.
This study has some limitations, such as the retrospective character and the small patient 
population of the study. Only 11 patients were included, however, all patients but one 
underwent all three 18F-FDG PET-CT scans and therefore it was possible to establish the 
changes in metabolic tumor activity during the neoadjuvant treatment in all patients. 
Possibly the interpretation of the third PET scan is biased by local inflammatory changes 
following the EBRT. These inflammatory changes might partly explain the significantly 
more pronounced decrease in metabolic tumor activity following the HILP then follow-
ing the EBRT, as found in the current series. Despite this potential bias due to radiation-in-
duced local inflammatory changes a decrease in metabolic tumor activity between scan 
1 and 3 was found, which theoretically might have been larger without these changes. 
For the purpose of this study, all data considering the metabolic tumor activity were ob-
tained from an additional analyses of the 18F-FDG PET-CT scans, since these data are not 
used in routine patient care. Interestingly, the EORTC-STBSG response score 26 could be 
used to explore the relationship between changes in metabolic tumor activity and histo-
pathologic response. However, the prognostic value of the STS response score according 
to the proportion of stainable tumor cells needs further validation.30
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Conclusions
This study identified the VOIgrad+ delineation technique as most reliable considering 
reproducibility when compared with the other delineation techniques during the 
multimodality neoadjuvant treatment of locally advanced ESTS. Moreover, the VOIgrad+ 
delineation technique was considerably less time-consuming to perform when com-
pared to the VOIman technique, potentially resulting in easier implementation in clinical 
practice. A significant decline in metabolic tumor activity during the treatment was 
found. The decrease in metabolic tumor activity was significantly more pronounced 
after HILP than after preoperative radiotherapy. TLG seems promising, but warrants 
further confirmation, as predictor for histopathologic response in ESTS. Further stud-
ies in larger ESTS patient-cohorts in which the investigated metabolic parameters and 
VOI delineation techniques are confirmed and validated as predictors for monitoring 
treatment response, for histopathologic response and for oncological outcome are 
warranted, as this will result in an increase in the clinical applicability of metabolic 
tumor activity assessments in longitudinal sarcoma 18F-FDG PET-CT studies. 
Supplemental methods
Bland-Altman analyses
Bland-Altman analyses were performed to determine the level of agreement between 
volume of interest (VOI) delineation techniques. Bland-Altman plots were created to 
compare the reference VOIman with the other three VOI delineation techniques. Plots 
comparing the difference vs. the average as well as the percentage difference vs. the 
average between the VOIman and the three other VOI delineation techniques were cre-
ated. The percentage difference was obtained by dividing the difference between the 
measured values by the average of these values. This was performed for SUVmean, 
TLG and MATV, and not for SUVmax and SUVpeak, since the measured values for these 
latter parameters were identical for all scans, independently of the VOI delineation 
technique that was used. 
Ranking of patients
Patients were ranked according to the SUVmean, TLG and MATV for each scan. SUV-
max and SUVpeak were not included, for the same reason as stated above. The high-
est value was given rank 1 and the lowest value was given rank 11. Using this ranking 
method, the VOI delineation techniques were compared. A difference in ranking of 
four or more between the highest and lowest rank was indicated in bold.
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This study aims to evaluate the applicability and prognostic val-
ue of the European Organization for Research and Treatment of 
Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) his-
topathological response score in extremity soft tissue sarcoma 
(ESTS) patients treated with neoadjuvant hyperthermic isolated 
limb perfusion (HILP) and delayed surgical resection. 
Methods
Patients treated between 1991 and 2016 were included. The his-
topathological tumor response was established in accordance 
with the EORTC-STBSG response score. The distribution of pa-
tients was assorted according to the 5-tier histopathological 
response score for tumor grade, histological subtype and HILP 
regimen. Predictors for local recurrence free survival (LRFS) and 
overall survival (OS) were identified through Kaplan-Meier and 
Cox regression analyses. 
Results
Ninety-one patients were included and their resection speci-
mens were reanalyzed. Which resulted in 11 Grade A (12.1%), ten 
Grade B (11.0%), 15 Grade C (16.5%), 22 Grade D (24.2%) and 33 
Grade E (36.3%) responses found among the series. The histo-
pathological response was significantly influenced by the HILP 
regimen used, p=0.033. Median follow-up was 65.0 (18.0-157.0) 
months. The histopathological response was not associated with 
LRFS nor OS. Resection margins, HILP regimen and adjuvant radi-
otherapy were associated with LRFS. Patients’ age, tumor grade, 
tumor size and histological subtype were predictors for OS. 
Conclusions
The EORTC-STBSG response score is applicable for determining 
the histopathological response to neoadjuvant ESTS treatment. 
However, this response does not seem to predict LRFS nor OS in 
locally advanced ESTS. 
Introduction
Soft tissue sarcomas (STS) are relatively rare and heterogeneous tumors, including 
over 50 histopathological subtypes.1 Approximately 50-60% of the STS arise in the 
extremities.2 In the Netherlands, 600-700 patients are diagnosed with a STS leading to 
300 STS related deaths annually.3,4
Extremity soft tissue sarcomas (ESTS) patients' survival is mainly determined by meta-
static potential, whereas local tumor treatment is of lesser importance. Consequently, 
local tumor treatment has evolved from amputation to limb salvage surgery com-
bined with radiotherapy.5,6 At presentation, some ESTS are considered to be locally 
advanced. Since the overall survival of ESTS patients is not increased by amputation of 
the affected limb,5 neoadjuvant hyperthermic isolated limb perfusion (HILP), followed 
by surgical resection, has been used to prevent amputation in locally advanced ESTS 
in over 40 centers throughout Europe,7,8 resulting in a limb salvage rate of 80-90%.9-12
Apart from neoadjuvant HILP, preoperative radiotherapy has been used in ESTS for 
decades. More recently, neoadjuvant chemotherapy has been tested in clinical trials 
in high-risk, but localized STS.13,14 To evaluate the histopathological response to these 
neoadjuvant treatment strategies, a standardized approach for the pathological ex-
amination of pretreated sarcomas was proposed by the European Organization for 
Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STB-
SG) in 2016.15 This protocol includes a 5-tier response score based on the percentage of 
stainable, potentially viable tumor cells, clearly different from earlier methods in which 
the percentage of tumor necrosis was scored to determine the tumor response. Nota-
bly, thus far, data from the literature did not prove that the amount of tumor necrosis 
is prognostic in pretreated STS.15,16 As tumor necrosis can be present in some STSs at 
diagnosis, it seems trustworthy to use the percentage of stainable cells in determin-
ing the histopathological response to neoadjuvant treatment. Recently, the first study 
applying the EORTC-STBSG response score found that it has no prognostic value with 
respect to recurrence free- and overall survival in a cohort of 100 extremity and trunk 
STS patients treated with radiotherapy prior to surgical resection.17
This single tertiary sarcoma-center study aims to assess the applicability and the prog-
nostic value of the EORTC-STBSG response score in locally advanced ESTS patients 
treated with neoadjuvant HILP followed by surgical resection of the residual tumor. 




The Institutional Review Board approved this study (case-number 2017.319). All con-
secutive patients over 18-years of age, with primary or recurrent, localized ESTS treated 
with neoadjuvant HILP followed by surgical resection, after 6-8 weeks, at the Univer-
sity Medical Center Groningen (UMCG) between 1991 and 2016 were analyzed. None 
of the patients were treated with neoadjuvant chemotherapy. Patients’ characteristics 
were obtained through medical record review. Patients for whom the required bi-
opsy/tumor specimen was not available or not suitable for reanalyzes were excluded 
from the cohort. 
Hyperthermic isolated limb perfusion
The HILP technique used, is based on the technique developed by Creech et al.18 and 
has previously been described in more detail.19 Under general anesthesia the major ar-
tery and vein of the affected limb were isolated and cannulated, thereby, isolating the 
blood flow of the limb from the systemic circulation. The cannulas were connected 
to an extracorporeal circuit. Subsequently, a tourniquet was applied to minimize leak-
age of the cytostatic agents into the systemic circulation. At the beginning, the per-
fusate consisted of interferon-γ (IFN-γ), tumor-necrosis factor-α (TNF-α) (Beromun®, 
Boehringer-Ingelheim GmbH, Vienna, Austria) and melphalan (Alkeran®, GlaxoSmith-
Kline Pharmaceuticals, Research Triangle Park, NC, USA). IFN-γ was soon abandoned, 
due to its ineffectiveness.7,9 Potential leakage of the cytostatic agents into the systemic 
circulation was continuously monitored by a precordial scintillation detector and I131-
human serum albumin.20,21 To perform the perfusion under controlled mild hyperther-
mia (38.5-40.0˚C), the limb was externally heated. Due to improvements in the HILP 
treatment, not all patients in this series were treated according the same HILP regi-
men. IFN-γ was abandoned, the TNF-α dose was reduced and the perfusion time was 
shortened.11 Until 2001 the perfusion duration was 90 min whereas from 2001 till now 
the duration was 60 min. The 90 min regimen was divided in 30 min of TNF-α perfu-
sion, followed by 60 min of melphalan perfusion. The 60 min regimen, started with 
15 min of TNF-α perfusion, then the melphalan was added and after another 45 min 
the perfusion was ended. Nowadays, 2 mg TNF-α is used for femoral and iliac perfu-
sions. Whereas 1 mg TNF-α is used for upper extremity and popliteal perfusions. These 
TNF-α doses are lower than the formerly used 3-4 mg TNF-α.11 The melphalan dose 
was based on the limb volume, 10 mg/L for upper extremity and popliteal perfusions, 
and 13 mg/L for iliac and femoral perfusions. Following the perfusion, the limb was 
flushed with saline, 2 L for upper extremity and popliteal perfusions, and 6 L for iliac 
and femoral perfusions. Following the flushing of the limb, the limb was filled with 
1U red blood cell concentrate. Afterwards, the cannulas were removed, the vessels 
repaired and the heparin antagonized with protamine sulphate. A closed fasciotomy 
of the anterior compartment of the lower leg was performed to prevent a compart-
ment syndrome.22,23 The first 24 hours following the procedure, the patient was closely 
observed in the medium care or intensive care unit. 
Methods
Prior to treatment, core-needle biopsies were performed for typing and grading of 
the tumors according to ‘American Joint Committee on Cancer’ and ‘World Health Or-
ganization (WHO)’ criteria.1,24 Tumor margins were classified according to the ‘Union 
for International Cancer Control’ R classification25 i.e. R0 for microscopically free tu-
mor margins, R1 for microscopically compromised margins and R2 for macroscopically 
compromised margins. As previously reported, the histopathological examination of 
STSs, including the determination of the percentage tumor necrosis of the resection 
specimens has been standardized at the UMCG since 1991.10,11,26 In 2017, all resection 
specimens were re-analyzed by a pathologist with special interest and expertise in 
STS, who was blinded for clinical outcome, to classify the histopathological tumor 
response in accordance with the 5-tier, stainable tumor cell based, EORTC-STBSG re-
sponse score; Grade A, no stainable tumor cells; Grade B, single stainable tumor cells 
or small clusters (overall below 1% of the whole specimen); Grade C, ≥1%-<10% stain-
able tumor cells; Grade D, ≥10%-<50% stainable tumor cells; Grade E, ≥50% stainable 
tumor cells.15 
The influence of tumor grade, histological subtype and HILP regimen on the histo-
pathological response was investigated by assorting patients' distribution for these 
parameters according to the five response grades. Histopathological responders were 
defined as having <10% stainable tumors cells, combining response grade A, B and C. 
The remaining patients were considered histopathological non-responders with re-
sponse grade D or E. Uni- and multivariate survival analyses were performed to iden-
tify associations between patient, tumor and treatment characteristics and 10-year 
local recurrence free survival (LRFS) or 10-year overall survival (OS). 
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Statistical analyses
Data are presented as frequencies and percentages for discrete variables and median 
and inter quartile ranges (IQR) for continuous variables. None of the variables were 
normally distributed. The Mann-Whitney U and Kruskal-Wallis test were used to com-
pare patients' distribution for tumor grade, histological subtype and HILP regimen 
according to their corresponding response scores. A p-value <0.05 was considered 
to indicate statistical significance. Oncological outcome was defined as time from 
date of HILP to event, either local recurrence or death. The Kaplan-Meier method and 
log-rank test were used for univariate survival analyses. Cox-regression was used to 
perform multivariate survival analyses. All potential predictors were included in a first 
multivariate cox-regression model. Backward selection was used, and predictors with 
a p<0.1 were included in the final model. Hazard ratios (HR) and 95% confidence inter-
vals (CI) are presented. SPSS version 23.0 (IBM SPSS Statistics for Windows, Version 23.0 
Armonk, NY: IBM Corp) was used. 
Results
Ninety-one patients, 48 male (52.7%), with a median age of 58.0 (44.0-65.0) years were 
included. Median tumor size was 9.0 (6.0-13.0) cm. Nearly 90% of the tumors were 
high grade and 83.5 % of the tumors were located in the lower extremity. Eighty-one 
patients (89.0%) were treated for primary disease, the remaining 10 patients (11.0%) 
for recurrent disease. The predominant histological subtype was pleomorphic undif-
ferentiated sarcoma not otherwise specified (Table 1). Not all patients underwent the 
same HILP regimen; 41 patients (45.1%) underwent the long and high dose HILP regi-
men, 12 patients (13.2%) underwent the short but high dose HILP regimen, 38 patients 
(41.8%) underwent the, now commonly accepted, short and low dose HILP regimen 
and 13 patients (14.3%) underwent a limb perfusion during the years that IFN-γ was 
included in the perfusate. Sixty patients (65.9%) underwent postoperative external 
beam radiotherapy (EBRT) following the HILP and surgical resection. Seventy patients 
(76.9%) underwent a R0 resection. The previously reported histopathological tumor 
responses were no change (NC), <50% necrosis, in 25 patients (27.5%); partial response 
(PR), 50-99% necrosis, in 50 patients (54.9%); and complete response (CR), 100% necro-
sis in 16 patients (17.6%). All 91 resection specimens were reanalyzed, and classified ac-
cording to the EORTC response score. Eleven patients had no stainable tumor cells left 
in the resection specimen, Grade A (12.1%). Ten patients had <1% stainable tumor cells, 
Grade B (11.0%). Fifteen patients had ≥1%-<10% stainable tumor cells, Grade C (16.5%). 
Twenty-two patients had ≥10%-<50% stainable tumor cells, Grade D (24.2%) and 
Table 1. Patient and tumor characteristics
Characteristic Total n=91 (%)
Age, years (IQR) 58.0 (44.0-65.0)
Gender
•	 Male 48 (52.7)
•	 Female 43 (47.3)
Tumor size, cm (IQR) 9.0 (6.0-13.0)
Tumor grade
•	 High 80 (87.9)
•	 Low 11 (12.1)
Tumor location
•	 Lower extremity 76 (83.5)
•	 Upper extremity 15 (16.5)
Histological subtype
•	 Pleomorphic undifferentiated/NOS 25 (27.5)
•	 Myxofibrosarcoma 14 (15.4)
•	 Myxoid liposarcoma 14 (15.4)
•	 Synovial sarcoma 11 (12.1)
•	 Leiomyosarcoma 9 (9.9)
•	 MPNST 3 (3.3)
•	 Pleomorphic rhabdomyosarcoma 3 (3.3)
•	 Pleomorphic liposarcoma 3 (3.3)
•	 Other 9 (9.9)
Local presentation
•	 Primary 81 (89.0)
•	 Recurrent 10 (11.0)
Data presented as n (%) or median (IQR). Abbreviations: IQR=interquartile 
range; NOS=not otherwise specified; MPNST=malignant peripheral nerve 
sheath tumor. 
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33 patients had ≥50% stainable tumor cells, Grade E (36.3%). Resulting in 36 respond-
ers (39.6%) and 55 non-responders (60.4%) (Table 2).
Table 3 presents patients' distribution for tumor grade, histological subtype and HILP 
regimen according to the five histopathological response grades. No significant 
differences in distribution were found for tumor grade and histological subtype 
among the EORTC grades, p=0.104 and 0.111 respectively. A significant difference in 
distribution among the response grades was found for the various HILP regimens, 
p=0.033. 
Follow-up
Median follow-up was 65.0 (18.0-157.0) months for the entire cohort. Ten patients 
(11.0%) developed a local recurrence and 47 patients (51.6%) developed distant me-
tastases. Ultimately, 43 patients (47.3%) died of disease and 8 patients (8.8%) died of 
other causes. At end of follow-up 40 patients (44.0%) were alive. Of which 36 patients 
(90.0%) had no evidence of disease, while 4 patients (10%) were alive with disease.
Univariate survival analyses displayed a significant influence of the HILP regimen, re-
section quality and adjuvant EBRT on 10-year LRFS. Showing a worse 10-year LRFS for 
patients treated with the short + high dose TNF-α HILP regimen, as well as for patients 
with compromised resection margins. Furthermore, postoperative irradiated patients 
Table 2. Treatment and tumor response characteristics
Characteristic Total n=91 (%)
HILP type
•	 Iliac 36 (39.6)
•	 Femoral 13 (14.3)
•	 Popliteal 27 (29.7)
•	 Axillar 12 (13.2)
•	 Brachial 3 (3.3)
HILP drugs
•	 IFN-γ/TNF-α/Melphalan 13 (14.3)
•	 TNF-α/Melphalan 78 (85.7)
HILP regimen
•	 Long (90 min) and high dose TNF-α 41 (45.1)
•	 Short (60 min) and high dose TNF-α 12 (13.2)
•	 Short (60min) and low dose TNF-α 38 (41.8)
Resection quality
•	 R0 70 (76.9)
•	 R1 18 (19.8)
•	 R2 3 (3.3)
Adjuvant EBRT
•	 No 31 (34.1)
•	 Yes 60 (65.9)
Table 2. Continued
Characteristic Total n=91 (%)
Tumor necrosis, historical
•	 NC; <50% 25 (27.5)
•	 PR; 50-99% 50 (54.9)
•	 CR; 100% 16 (17.6)
EORTC STS response score
•	 Grade A 11 (12.1)
•	 Grade B 10 (11.0)
•	 Grade C 15 (16.5)
•	 Grade D 22 (24.2)
•	 Grade E 33 (36.3)
Histopathological responder
•	 No 55 (60.4)
•	 Yes 36 (39.6)
Data presented as n (%). Abbreviations: HILP=hyperthermic isolated limb 
perfusion; IFN-γ=interferon-γ; TNF-α=tumor necrosis factor-α; EBRT=external 
beam radiotherapy; NC=no change; PR=partial response; CR=complete re-
sponse. EORTC STS response score: Grade A, no stainable tumor cells; Grade 
B, single stainable tumor cells or small clusters (overall below 1% of the whole 
specimen); Grade C, ≥1%-<10% stainable tumor cells; Grade D, ≥10%-<50% 
stainable tumor cells; Grade E, ≥50% stainable tumor cells.15 
Histopathological responders having <10% stainable tumor cells.
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had a 10-year LRFS of 89.5% compared to 65.2% for patients who did not undergo ad-
juvant EBRT, p=0.004. No significant association between the histopathological tumor 
response and 10-year LRFS was found. Due to the limited amount of local recurrences, 
no multivariate analyses for LRFS was performed. Patients’ age at start of treatment, 
tumor grade, histological subtype and adjuvant EBRT were significantly associated 
with 10-year OS in univariate analyses (Table 4). Multivariate cox-regression analyses 
identified patients’ age 1.04 (1.01-1.06), p=0.003; tumor size 1.09 (1.03-1.15), p=0.001; high 
tumor grade 4.52 (1.12-18.23), p=0.034; and histological subtype, p=0.011 to be predic-
tors for 10-year OS (Table 5). Leiomyosarcoma and MPNST were associated with a sig-
nificantly worse 10-year OS. 
Discussion
This study shows that the EORTC-STBSG response score can be applied to determine 
the histopathological tumor response following neoadjuvant HILP and delayed sur-
gical resection in locally advanced ESTS. A significant difference in the percentage 
stainable tumor cells was found for the various HILP regimens used during the study 
period. However, no association between the histopathological tumor response, i.e. 
tumor necrosis or stainable tumor cells, and LRFS or OS was found. 
STS are heterogeneous tumors and the neoadjuvant treatment-induced tumor 
changes can differ throughout the tumor. Furthermore, STS tend to have a necrotic 
tumor center at presentation due to rapid tumor growth. At histopathological ex-
amination after resection it is impossible to determine the cause of necrosis (pre-
existent or treatment-induced). Earlier studies showed that the percentage of tumor 
necrosis following neoadjuvant treatment is not prognostic for oncological outcome 
in ESTS.15,16 Therefore the EORTC response score may have greater potential for the 
determination of the therapy effect compared to the determination of the percent-
age tumor necrosis. However, as our results show, the EORTC response score does not 
seem to influence the LRFS or OS. 
In bone sarcomas, especially osteosarcomas, the use of tumor necrosis and later the 
proportion of vital tumor cells has been established, and was found to be prognos-
tic.27-29 Subsequently, histopathological responders, <10% vital tumor cells, and non-
responders in osteosarcomas were identified by the WHO.1 The standardized protocol 
for the pathological examination of pretreated STS as proposed by the EORTC-STBSG 
includes a 5-tier STS response score to interpret the efficacy of the various neoadju-








































































































































































































































































































































































































































































































































































































































































































































































Table 4. Univariate analyses of the association between patient, tumor and 
treatment characteristics and 10-year LRFS and OS
Characteristic 10-year LRFS 10-year OS
n (%) p-value (%) p-value
All patients 91 81.6 NA 45.7 NA
Age, years 0.507 0.003
•	 <45 23 83.7 73.7
•	 45-54 17 68.6 45.4
•	 55-65 30 91.6 43.3
•	 ≥ 65 21 79.0 15.9
Gender 0.178 0.733
•	 Male 48 90.9 43.8
•	 Female 43 73.0 48.2
Tumor size (cm; 4 missing) 0.944 0.442
•	 <5 16 79.1 50.0
•	 ≥ 5 71 82.8 44.5
Tumor grade 0.529 0.050
•	 High 80 80.9 42.3
•	 Low 11 85.7 71.6
Tumor location 0.154 0.617
•	 Lower extremity 76 85.0 46.9
•	 Upper extremity 15 60.9 40.0
Histological subtype 0.829 0.011
•	 Pleomorphic undifferentiated/NOS 25 84.3 32.0
•	 Myxofibrosarcoma 14 80.2 42.9
•	 Myxoid liposarcoma 14 88.9 71.4
•	 Synovial sarcoma 11 83.3 72.7
•	 Leiomyosarcoma 9 43.8 22.2
•	 MPNST 3 NA* 0.0
•	 Pleomorphic rhabdomyosarcoma 3 NA* 66.7
•	 Pleomorphic liposarcoma 3 NA* 33.3
•	 Other 9 80.0 53.3
Local presentation 0.116 0.477
•	 Primary 81 84.7 43.9
•	 Recurrent 10 63.5 60.0
HILP type 0.320 0.085
•	 Iliac 36 72.7 41.3
•	 Femoral 13 NA* 44.9
•	 Popliteal 27 92.0 55.6
•	 Axillar 12 60.2 50.0
•	 Brachial 3 NA* 0.0
Table 4. Continued
Characteristic 10-year LRFS 10-year OS
n (%) p-value (%) p-value
HILP drugs 0.653 0.903
•	 IFN-γ/TNF-α/Melphalan 13 76.4 46.2
•	 TNF-α/Melphalan 78 82.7 45.6
HILP regimen 0.008 0.634
•	 Long (90min) + high dose TNF- α 41 84.2 41.5
•	 Short (60 min) + high dose TNF-α 12 48.9 50.0
•	 Short (60min) + low dose TNF-α 38 97.2 49.3
Resection quality 0.006 0.704
•	 R0 70 88.0 45.5
•	 R1 18 59.9 50.0
•	 R2 3 66.7 33.3
Adjuvant EBRT 0.004 0.047
•	 No 31 65.2 34.9
•	 Yes 60 89.5 51.5
Tumor necrosis, historical 0.931 0.928
•	 NC; <50% necrosis 25 81.7 50.9
•	 PR; 50-99% necrosis 50 84.2 44.0
•	 CR; 100% necrosis 16 76.2 43.8
EORTC STS response score 0.514 0.260
•	 Grade A 11 85.7 45.5
•	 Grade B 10 83.3 60.0
•	 Grade C 15 NA* 26.7
•	 Grade D 22 81.8 58.7
•	 Grade E 33 72.6 42.4
Histopathological responder 0.156 0.729
•	 No 55 77.5 48.8
•	 Yes 36 87.8 41.7
Data presented as actuarial survival percentages, log-rank test was used for comparison of 
characteristics. *Not applicable, all cases were censored. Abbreviations: LRFS=local recur-
rence free survival; OS=overall survival; NA=not applicable; HILP=hyperthermic isolated limb 
perfusion; IFN-γ=interferon-γ; TNF-α=tumor-necrosis factor-α ; NOS=not otherwise speci-
fied; MPNST=malignant peripheral nerve sheath tumor; NC=no change; PR=partial response; 
CR=complete response; EORTC=European Organization for Research and Treatment of Cancer; 
STS=soft tissue sarcoma. 
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The current study could not establish an association between this STS response score 
and LRFS or OS. Subsequently patients were divided into two groups, being histo-
pathological responders and non-responders to create larger groups for statistical 
analyses. The cut-off value used was based on the cut-off value currently used to de-
termine response to chemotherapy for osteosarcomas. Histopathological responders 
were defined as having residual tumors containing <10% stainable tumor cells. How-
ever, as Table 4 shows being a histopathological responder did not influence 10-year 
LRFS nor OS. 
The first study applying the EORTC-STBSG response score, showed no prognostic 
value considering recurrence free- and overall survival in a cohort of 100 extremity 
and trunk STS patients treated with radiotherapy prior to surgical resection of the re-
sidual tumor.17 Till date, there is no data addressing the prognostic value of the EORTC 
response score following chemotherapy in STS. As the use of (neo)adjuvant chemo-
therapy is controversial and under ongoing investigation in localized STS,14 it might be 
of interest to include the EORTC-STBSG response score as parameter in current and 
future studies, especially since the histopathological tumor response of the primary 
tumor might provide additional information regarding the chemosensitivity of poten-
tial metastases developing during follow-up in these patients. 
The current study has some limitations. The retrospective nature affects data collec-
tion and selection of patients. Not all patients in this cohort underwent the same 
HILP regimen. Over time IFN-γ was abandoned due to its ineffectiveness, the TNF-α 
dose was lowered and the perfusion duration was shortened. These improvements 
in HILP treatment were found to be safe and effective in terms of long-term patient 
outcome.7,9,11 However, as established in the current series these changes in HILP regi-
men significantly influence the histopathological response when classified according 
to the EORTC-STBSG score. 
The current study shows an univariate association between the various HILP regi-
mens, resection margins and adjuvant EBRT, and 10-year LRFS. The significant effect 
of the HILP regimen on LRFS was unexpected, and seems to be explained by a worse 
LRFS for patients who underwent the short and high dose regimen. We cannot fully 
explain this worse LRFS for these patients. However, this regimen is no longer in use 
as the shorter and reduced dose regimen was shown to be oncologically safe in 2011.11 
In corroboration with earlier studies, we found that the 10-year OS is predicted by 
patients’ age, tumor size, tumor grade and histological subtype through multivariate 
analyses in the current series.1,30-33 However, there are studies showing that local recur-
rence development is a predictor for distant metastases and (disease-specific) death 
as well.34-36 Due to small sample size and low event rate i.e. local recurrence rate, we 
were not able to perform multivariate analyses for LRFS. Besides, nearly 66% of the 
patients in this cohort received postoperative EBRT following the HILP and surgical 
resection, and although the adjuvant EBRT does not influence the histopathological 
response, it is well-accepted that postoperative EBRT following HILP and surgical re-
section lowers the local recurrence risk.26 Since postoperative EBRT lowers the local 
recurrence risk, the tumor margin combined with the tumor response at the clos-
est surgical margin might be of prognostic value for local recurrence development. 
Studies addressing the influence of the histopathological response at the closest 
Table 5. Multivariate cox-regression analyses of the association be-
tween patient, tumor and treatment characteristics and 10-year OS
Characteristic Overall survival
HR (95% CI) p-value
Age, years 1.04 (1.01-1.06) 0.003
Tumor size (cm) 1.09 (1.03-1.15) 0.001
Tumor grade 0.034
•	 Low 1
•	 High 4.52 (1.12-18.23)
Histological subtype 0.011
•	 Myxoid liposarcoma 1
•	 Leiomyosarcoma 5.86 (1.47-23.34)
•	 Myxofibrosarcoma 1.52 (0.36-6.39)
•	 Synovial sarcoma 1.54 (0.29-8.23)
•	 MPNST 10.66 (1.92-59.37)
•	 Pleomorphic undifferentiated/NOS 2.76 (0.71-10.69)
•	 Pleomorphic rhabdomyosarcoma 0.65 (0.06-6.63)
•	 Pleomorphic liposarcoma 0.75 (0.11-5.05)
•	 Other 1.25 (0.26-6.08)
Abbreviations: OS=overall survival; HR=hazard ratio; CI=confidence interval; NOS=not 
otherwise specified. 
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surgical margin combined with the role of postoperative EBRT in these cases are 
necessary.
In conclusion, we corroborated earlier studies, showing that the histopathological tu-
mor response, scored by the relative amount of tumor necrosis or stainable tumor 
cells, has no prognostic value considering LRFS and OS in pretreated STS. Therefore, 
the histopathological response should not be used in making treatment decisions at 
this point. Nevertheless, it is important to standardize the pathological examination of 
pretreated STS and to conform to the use of the EORTC-STBSG response score. In pre-
treated STS the use of stainable tumor cells seems rational and trustworthy, and fur-
ther prospective research considering its prognostic value for oncological outcome is 
warranted. 
Conclusions
In STS management, the proposed standardization of histopathological examination 
of pretreated STS by the EORTC-STBSG is a step forwards. However, in our series the 
histopathological response (either stainable tumor cells or tumor necrosis) of these 
tumors does not seem to have prognostic value considering LRFS and OS and there-
fore it should not be used in making treatment decisions at this point. Further pro-
spective studies addressing the prognostic value of the histopathological response, 
preferably including vital tumor cells, in pretreated STS are necessary.
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Summary & conclusions
Part I - Treatment of resectable extremity soft tissue sarcoma
As limb-amputation was shown not to improve survival rates, surgical resection of the 
tumor has become the mainstay of extremity soft tissue sarcoma (ESTS) treatment 
since the randomized trials by Rosenberg et al. in the 1980s.1 Accordingly, the treat-
ment of ESTS has evolved from limb-amputation to a more conservative multimodal-
ity approach.2,3 This enables clinicians to prevent limb-amputation in >90% of the pa-
tients nowadays.4-7 External beam radiotherapy (EBRT) is used commonly in addition 
to surgical resection to gain local tumor control. In 2002, the randomized controlled 
trial by O’Sullivan et al. showed a significant increase in major wound complications 
(MWC) following preoperative EBRT, when compared with postoperative EBRT in ad-
dition to surgical resection.3 However, as postoperative EBRT involves higher radiation 
doses and larger radiation fields it is associated with an increased risk for the develop-
ment of fibrosis, possibly leading to a detrimental long-term functional outcome.8 
Chapter 2 aimed to identify predictors for MWC development following EBRT and 
surgical resection in ESTS treatment. In preoperative irradiated patients a MWC rate of 
39.7% was found, whereas 20.3% of the postoperatively irradiated patients developed 
a MWC in our series. Subsequently, preoperative EBRT was identified as significant 
predictor for MWC development, while a trend towards an increased MWC risk was 
found for patients' age, timing of wound closure and tumor margins. Besides, a shift 
in the distribution of patients treated with preoperative or postoperative EBRT in ad-
dition to surgical resection was shown. Hence, out of the 36 patients treated between 
2005 and 2007 one patient underwent preoperative EBRT, whereas 35 out of the 39 
patients treated between 2014-2016 underwent preoperative EBRT. 
Part II - Treatment of locally advanced extremity soft tissue sarcoma
The treatment of locally advanced, or primarily non-resectable, ESTS is particularly 
challenging. The involvement of neurovascular structures, bony involvement or large 
tumor size, involving multiple compartments, necessitate an extensive treatment 
regimen to facilitate limb salvage treatment in these locally advanced ESTS.9-11 Hyper-
thermic isolated limb perfusion (HILP) with melphalan and tumor necrosis factor-α 
(TNF-α) followed by surgical resection of the tumor and postoperative EBRT in se-
lected cases is used throughout Europe to prevent limb-amputation in patients who 
would otherwise be considered for ablative surgery.12 Traditionally HILP was followed 
by surgical resection of the tumor (after 6-8 weeks) and if indicated, postoperative 
EBRT starting 6-8 weeks following the surgical resection was administered.10 Chap-
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ter 3 presents a shorter but intensive treatment regimen for locally advanced ESTS, 
consisting of HILP, preoperative EBRT and surgical resection of the tumor remnant. 
This intensified treatment was found to be feasible and safe in locally advanced ESTS, 
while the oncological outcome was found to be similar to the traditionally used regi-
men. As highlighted in chapter 4, limb-salvage treatment is not or no longer feasible 
for some patients. In these cases, limb-amputation is the only remaining treatment 
option to obtain local tumor control. Non-resectability of the tumor caused by large 
tumor size was found to be the main indication for a primary amputation, whereas 
a local recurrence which could not be treated with a limb salvage treatment option 
was the predominant indication to perform a non-primary amputation. Furthermore, 
we showed in chapter 4 that while the time between diagnosis and amputation dif-
fers significantly for primary and non-primary amputated patients, their oncological 
outcome seems to be comparable. 
Part III - Metabolic and histopathological tumor responses in pretreated 
extremity soft tissue sarcoma
The more routine use of neoadjuvant treatment modalities i.e. HILP, preoperative EBRT 
and neoadjuvant systemic chemotherapy in localized ESTS has consequently led to 
more research focusing on the assessment of neoadjuvant treatment-efficacy. Since 
the 1990s, fluorine-18-fluorodeoxyglucose positron emission tomography with com-
puted tomography (18F-FDG PET-CT) scans have been used to assess and quantify 
the changes in metabolic tumor activity, commonly expressed as maximum stand-
ardized uptake value (SUVmax) and SUVmean.13 In chapter 5 we present the use of 
various volume of interest (VOI) delineation techniques for the quantification of the 
metabolic tumor activity of locally advanced ESTS during neoadjuvant multimodal-
ity treatment, consisting of neoadjuvant HILP, preoperative EBRT and surgical resec-
tion. In addition to the commonly used SUVmax and SUVmean, SUVpeak, total lesion 
glycolysis (TLG) and metabolically-active tumor volume (MATV) were obtained for all 
scans. Considering the VOI delineation techniques, the VOIgrad+ delineation technique 
was shown to be most reliable considering reproducibility when compared with the 
three other delineation techniques. A significant decline in metabolic tumor activity 
during this treatment was found, this decline was most pronounced following the 
HILP. TLG was shown to be promising as predictor for histopathological response in 
pretreated ESTS, however, it warrants further confirmation in larger patient-cohorts. 
The histopathological response of pretreated ESTS was further studied in chapter 6. 
The percentage tumor necrosis has been used commonly to express the extent of 
the histopathological tumor response following neoadjuvant treatment. However, 
the percentage tumor necrosis at histopathological examination in pretreated ESTS is 
not prognostic for oncological outcome.14 Possibly, because the amount of treatment-
induced necrosis cannot be distinguished from tumor necrosis already present, due 
to tumor heterogeneity, prior to treatment.15 Chapter 6 establishes that the European 
Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma 
Group response score15 is applicable for the determination of the histopathological 
tumor response in pretreated ESTS. However, it seems that neither local recurrence 
free survival nor overall survival are predicted by this stainable, possibly viable, tumor 
cell based response score. 
In conclusion, the preceding chapters of this thesis address various aspects and ad-
vancements in the treatment of, locally advanced, localized ESTS. Insights in the on-
going and future research in the treatment of, locally advanced, localized ESTS will be 
addressed in the following chapter; Chapter 8 – Future perspectives. 
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Samenvatting en conclusies
Deel I - Behandeling van het resectabele weke delen sarcoom van de ex-
tremiteiten
Nadat Rosenberg en collega's in de jaren 80 aantoonden dat de overleving van 
patiënten met een weke delen sarcoom van de extremiteiten niet verbeterde door 
een amputatie van het aangedane ledemaat, is de chirurgische resectie van de tu-
mor de hoeksteen van de behandeling geworden.1 Hierdoor is door de jaren heen, 
de behandeling van het weke delen sarcoom van de extremiteiten geëvolueerd van 
een amputatie bij het merendeel van de patiënten tot een multimodale behande-
ling gericht op het behouden van het aangedane ledemaat.2,3 Tegenwoordig kan dan 
ook bij >90% van deze patiënten een amputatie voorkomen worden.4-7 Om lokale 
tumorcontrole te verkrijgen, wordt in aanvulling op de chirurgische resectie van de 
tumor vaak radiotherapie (RT) toegepast. In 2002 toonde de gerandomiseerde studie 
van O'Sullivan en collega's een significante toename van het aantal patiënten met 
een ernstige wondcomplicatie na het gebruik van preoperatieve RT in vergelijking 
met patiënten die postoperatieve RT ondergingen in aanvulling op de chirurgische 
resectie van de tumor.3 In vergelijking met preoperatieve RT, wordt postoperatieve 
RT gekenmerkt door hogere stralingsdoses en grotere bestralingsvelden. Hierdoor is 
postoperatieve RT geassocieerd met een toegenomen risico op het ontwikkelen van 
fibrose op de lange termijn, welke mogelijk leidt tot een verslechtering van de func-
tionele uitkomst voor de patiënt.8 Hoofdstuk 2 heeft als doel om voorspellers voor 
het ontwikkelen van een ernstige wondcomplicatie na RT en chirurgische resectie 
van een weke delen sarcoom van de extremiteit te identificeren. Van de preoperatief 
bestraalde patiënten in ons cohort ontwikkelde 39,7% een ernstige wondcomplicatie, 
terwijl 20,3% van de postoperatief bestraalde patiënten een ernstige wondcompli-
catie ontwikkelden. Het gebruik van preoperatieve RT werd dan ook geïdentificeerd 
als significante voorspeller voor het ontwikkelen van een ernstige wondcomplicatie. 
Daarnaast werd een trend voor het ontwikkelen van een ernstige wondcomplicatie 
gevonden voor de timing van het sluiten van de wond, de resectiemarges en het toe-
nemen van de leeftijd van de patiënt. Verder werd er een verschuiving in de verdeling 
van pre- en postoperatief bestraalde patiënten gevonden. Tussen 2005 en 2007 on-
derging namelijk één van de 36 behandelde patiënten preoperatieve RT, terwijl tus-
sen 2014 en 2016 35 van de 39 behandelde patiënten preoperatieve RT ondergingen. 
Deel II - Behandeling van het 'lokaal uitgebreid' weke delen sarcoom van 
de extremiteiten
De behandeling van het 'lokaal uitgebreid', of het primair niet-resectabele, weke delen 
sarcoom van de extremiteiten vormt een uitdaging. De betrokkenheid van neurovas-
culaire structuren, botten, maar ook tumorgrootte en de betrokkenheid van meerdere 
compartimenten maken een uitgebreide tumorbehandeling noodzakelijk om zo een 
amputatie te voorkomen.9-11 In Europa wordt hypertherme geïsoleerde ledemaatper-
fusie, met melfalan en tumor necrosis factor-α (TNF-α), gevolgd door chirurgische 
resectie van de tumor en voor sommige geselecteerde patiënten postoperatieve 
RT gebruikt, om een amputatie te voorkomen in het geval van een lokaal uitgebreid 
weke delen sarcoom van de extremiteiten.12 Van oudsher werd de ledemaatperfusie 
gevolgd door een chirurgische resectie van de tumor (na 6-8 weken) en op indicatie 
werd dit gevolgd door postoperatieve RT. De RT startte dan ongeveer 6-8 weken na 
de resectie van de tumor.10 Hoofdstuk 3 beschrijft een kortere maar meer intensieve 
behandelstrategie voor de behandeling van het lokaal uitgebreide weke delen sar-
coom van de extremiteiten. Deze behandeling bestaat uit: hypertherme geïsoleerde 
ledemaatperfusie, preoperatieve RT en chirurgische resectie van de tumor rest. Deze 
geïntensiveerde behandeling blijkt haalbaar en veilig te zijn, terwijl de oncologische 
uitkomsten van deze patiënten vergelijkbaar zijn met die van de patiënten die de 
conventionele behandeling ondergingen. Zoals hoofdstuk 4 beschrijft, is het voor 
sommige patiënten niet, of niet meer, mogelijk om een ledemaatsparende behande-
ling te ondergaan. In deze gevallen is een amputatie de enige behandelmogelijkheid 
die overblijft om de lokale tumor onder controle te krijgen. Tumorgrootte was de be-
langrijkste indicatie voor het uitvoeren van een primaire amputatie, terwijl een lokaal 
recidief waarbij geen ledemaatsparende opties meer mogelijk waren, de voornaam-
ste reden was om een niet-primaire amputatie uit te voeren. Bovendien toont hoofd-
stuk 4 aan dat, hoewel de tijd tussen diagnose en amputatie significant verschillend is 
voor patiënten die een primaire dan wel een niet-primaire amputatie ondergaan, hun 
oncologische uitkomsten wel vergelijkbaar lijken te zijn. 
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Deel III - Metabole en histopathologische tumor respons van  
voorbehandelde weke delen sarcomen van de extremiteiten
De toename in het routinematig gebruik van neoadjuvante behandelmodaliteiten, als 
hypertherme geïsoleerde ledemaatperfusie, preoperatieve RT en neoadjuvante sys-
temische chemotherapie in het gelokaliseerde weke delen sarcoom van de extremi-
teiten heeft ertoe geleid dat meer onderzoek gefocust is op het vaststellen van de 
effectiviteit van deze neoadjuvante behandelingen. Sinds de jaren 90 worden fluor-
18-fluordeoxyglucose positron emissie tomografie met computer tomografie (18F-FDG 
PET-CT) scans gebruikt om de verandering in metabole tumor activiteit vast te stel-
len en te kwantificeren. Hierbij wordt de metabole tumoractiviteit vaak uitgedrukt als 
de maximale standardized uptake value (SUVmax) en de gemiddelde standardized 
uptake value (SUVmean).13 In hoofdstuk 5 presenteren we het gebruik van verschil-
lende volume of interest (VOI) delineatietechnieken voor het kwantificeren van de 
metabole tumoractiviteit van het lokaal uitgebreid weke delen sarcoom van de ex-
tremiteiten gedurende de multimodale neoadjuvante behandeling. Deze behande-
ling bestaat uit hypertherme geïsoleerde ledemaatperfusie, preoperatieve RT en chi-
rurgische resectie van de tumor. Naast de algemeen gebruikte SUVmax en SUVmean, 
werden voor alle scans ook de SUVpeak, de totale glycolyse en het metabool-actieve 
tumor volume (MATV) vastgesteld. Met betrekking tot de reproduceerbaarheid, blijkt 
de VOIgrad+ delineatie techniek het meest betrouwbaar te zijn in vergelijking met de 
drie andere delineatietechnieken. Gedurende deze behandeling is een significante 
afname in metabole tumoractiviteit gevonden, welke het meest uitgesproken lijkt te 
zijn in de periode na de ledemaatperfusie. Verder lijkt de totale glycolyse veelbelov-
end te zijn als voorspeller van de histopathologische tumorrespons in voorbehan-
delde weke delen sarcomen van de extremiteiten. Echter, verder onderzoek in grotere 
patiëntcohorten is noodzakelijk om deze uitkomsten te bevestigen. De histopatholo-
gische tumor respons van voorbehandelde weke delen sarcomen van de extremitei-
ten is nader onderzocht in hoofdstuk 6. Het percentage tumornecrose wordt van 
oudsher vaak gebruikt om de histopathologische tumorrespons op de neoadjuvante 
behandeling vast te stellen. Echter, het percentage tumornecrose welke bij histo-
pathologisch onderzoek wordt vastgesteld blijkt niet voorspellend te zijn voor de 
oncologische uitkomst van de patiënt.14 Mogelijk wordt dit veroorzaakt doordat de 
hoeveelheid tumornecrose die door de behandeling geïnduceerd is niet kan worden 
onderscheiden van de necrose die door de heterogeniteit van de tumor al aanwezig 
was voor de start van de behandeling.15 Hoofdstuk 6 laat zien dat de histopatholo-
gische response score van de 'European Organization for Research and Treatment of 
Cancer-Soft Tissue and Bone Sarcoma Group'15 gebruikt kan worden om de tumor 
respons vast te stellen in voorbehandelde weke delen sarcomen van de extremiteiten. 
Echter, het lijkt dat noch de lokaal recidief vrije overleving noch de totale overleving 
van deze patiënten voorspeld kan worden met behulp van deze op kleurbare, mo-
gelijk vitale, tumorcellen gebaseerde respons score. 
In conclusie, de voorgaande hoofdstukken van dit proefschrift behandelen ver-
schillende aspecten en vorderingen in de behandeling van het (lokaal uitgebreide) 
gelokaliseerde weke delen sarcoom van de extremiteiten. Verschillende inzichten in 
het voortdurende en toekomstige onderzoek naar de behandeling van het (lokaal 
uitgebreide) gelokaliseerde weke delen sarcoom van de extremiteiten zullen nader 
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Radiotherapy in extremity soft tissue sarcoma
Surgical resection of the tumor combined with external beam radiotherapy (EBRT) 
is standard of care in most localized resectable extremity soft tissue sarcomas (ESTS) 
nowadays. EBRT is essential in most patients to obtain sufficient local tumor control, 
and can be administered either in the pre- or in the postoperative setting. The preop-
erative timing of EBRT is a known risk factor for the development of a major wound 
complication following surgical resection of the tumor remnant. Whereas postopera-
tive EBRT induces more long-term fibrosis, edema and joint stiffness due to the larger 
radiation fields and higher doses, resulting in a detrimental functional outcome for 
these patients.1 Several advances in EBRT regimens and techniques in the treatment 
of ESTS are under current and ongoing investigation with the ultimate goal to achieve 
optimal oncological results while reducing treatment-induced short- and long-term 
morbidity.
Although data regarding hypofractionation of preoperative EBRT in ESTS is scarce, 
recent results seem to be promising. A 5x5 Gy hypofractionated preoperative EBRT 
regimen followed by surgical resection of the tumor within one week was found to 
be oncologically safe, while only 7% of these patients required a surgical intervention 
for the treatment of a wound complication in this series.2 Furthermore, the prelimi-
nary results of an ongoing phase II trial (NCT02701153) on preoperative hypofraction-
ated EBRT were recently presented at the Connective Tissue Oncology Society An-
nual Meeting, showing a 17% major wound complication rate in the patients treated.3 
These wound complications rates seem to be lower than the 30-35% major wound 
complication rate following conventional fractionated (25x2 Gy) preoperative EBRT.4-8 
Therefore these new fractionation regimens might provide a useful alternative for the 
conventional EBRT treatment schemes. 
Long-term morbidity resulting in a deteriorated functional outcome seems to be 
more pronounced in postoperative irradiated patients, although, the development of 
a major wound complication also is associated with an impairment of functional out-
come.9,10 To reduce the long-term treatment-induced morbidity following postopera-
tive EBRT, a randomized controlled trial was initiated in which patients are randomized 
into; Arm A, 25x2 Gy preoperative intensity modulated radiation therapy (IMRT), or 
Arm B, 25x2 Gy postoperative IMRT followed by a 8x2 Gy boost in case of positive surgi-
cal margins (NCT02565498). The conventionally used postoperative dose of 60-70 Gy 
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is thus lowered to 50 Gy in this trial, which might contribute to a reduction of the EBRT 
induced long-term morbidity. 
EBRT techniques are subject to advancements as well. The above mentioned rand-
omized trial compares the use of pre- and postoperative IMRT. Considering the onco-
logical outcome, IMRT was shown to be associated with a significantly reduced local 
recurrence risk when compared with the commonly used three-dimensional confor-
mal radiotherapy (3D-CRT).11 Moreover, a phase II study tended to show a reduced 
wound complication risk following preoperative IMRT in comparison with 3D-CRT, as 
IMRT enables the radiation oncologist to deliver adequate radiation doses to the tu-
mor volume, while it allows a dose reduction in tissues surrounding the tumor.12,13 This 
reduced wound complication risk following IMRT needs further validation in larger 
prospective trials. Besides the technical advancements in photon-based EBRT, pro-
ton beam radiotherapy (PBT) is used more commonly in soft tissue sarcoma (STS).14 
In some cases PBT might be advantageous over photon-based EBRT owing to the 
unique energy absorption profile. The energy of the protons is delivered to a narrow 
range at the depth of the tumor, this peak in energy deposition is also known as the 
Bragg Peak. Beyond, or distally from the Bragg Peak, almost no energy is delivered, 
which allows for a significant reduction of the radiation dose delivered to the normal 
tissues surrounding the tumor.14,15 The selection of patients that might benefit from 
PBT over the commonly used photon-based EBRT is challenging and in the Neth-
erlands a model-based approach has been developed, which was adopted by the 
Dutch Health Council.15 PBT is currently under ongoing investigation (NCT01561495) 
for ESTS, but its role might be limited as 3D-CRT and IMRT techniques seem to be suf-
ficient for adequate radiotherapy planning and treatment in most ESTS patients, while 
PBT seems to be beneficial in paediatric and retroperitoneal sarcomas.14 
Plastic surgical reconstructions and wound management 
Plastic surgical reconstructions have been used to obtain wound closure following 
extensive surgical resections in ESTS. In preoperatively irradiated patients, flap recon-
structions permit the transposition from healthy tissue to the previously irradiated 
surgical area which results in an alteration in the risk for the development of a major 
wound complication.16 Although direct plastic surgical reconstructions may compli-
cate the surgical procedure, they also seem to lower the major wound complication 
risk in preoperatively irradiated patients.8,17 Hence, in patients who underwent direct 
reconstructive surgery, the preoperative radiotherapy was not associated with major 
wound complication development.18 Further studies considering the appropriate pa-
tient selection for plastic surgical reconstructions, as well as studies investigating the 
'protective' influence of direct flap reconstructions are necessary. 
Besides the advancements in EBRT techniques and plastic surgical reconstructions, 
several improvements in the postoperative wound care are currently under investiga-
tion to minimize the risk for the development of a major wound complication. The 
use of postoperative hyperbaric oxygen therapy (HBOT) is currently under investiga-
tion in a randomized trial (NCT03144206). This trial divides preoperatively irradiated 
patients into two groups. Patients in group I undergo the administration of HBOT di-
rectly following the surgical resection of the tumor, while patients in group II do not. 
HBOT comprises an intensive treatment commonly consisting of 20-40 daily sessions, 
during which the patient breathes 100% oxygen in a pressurized (2-3 atmosphere ab-
solute pressure (ATA)) chamber. During this treatment the partial pressure of oxygen 
in the patients' blood and accordingly in the damaged tissues is extremely increased, 
thereby it was shown to be beneficial for patients with ischemic wounds and late radi-
ation-induced tissue injuries.19-21 Secondly, negative pressure wound therapy (NPWT) 
is investigated in preoperatively irradiated lower ESTS patients (NCT02638298). Pa-
tients are randomized into the use of NPWT or not. Accordingly, following the surgical 
resection of the tumor and closure of the wounds, NPWT is applied for half of the 
patients, while the other half of patients undergo traditional wound management 
with dry gauzes. NPWT provides gentle suction on the wound, and its influence on 
the development of postoperative wound complications is investigated. 
High risk localized extremity soft tissue sarcoma
Patients' oncological outcome following extremity soft tissue sarcoma treatment is 
mainly determined by the tumors potential to metastasize distantly, mainly to the 
lungs. Accordingly, several studies investigating the influence of (neo)adjuvant chem-
otherapy in high risk localized, non-metastatic, ESTS have been conducted during the 
last years.22-24 The data available is somewhat inconsistent and conflicting, making the 
implementation of standardized (neo)adjuvant chemotherapy in localized ESTS trou-
blesome.25 An improvement in oncological outcome was found for a subgroup of lo-
calized ESTS patients treated with (neo)adjuvant chemotherapy, but further research 
is needed to correctly identify those patients who might benefit from the treatment.26 
Locally advanced extremity soft tissue sarcoma
The treatment of locally advanced ESTS is particularly demanding and multiple re-
gional chemotherapy, i.e. hyperthermic isolated limb perfusion or isolated limb in-
fusion, based regimens have been used to obtain limb-salvage to date. As recently 
presented in a large systematic review various chemotherapy agents, regimens and 
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techniques are used throughout the world for the treatment of locally advanced 
ESTS.27 The treatment of this rare subgroup of patients is especially hard to standard-
ize, necessitating the need for the further centralization of sarcoma treatment in order 
to effectuate a patient-tailored treatment approach based on the counsel of a multi-
disciplinary sarcoma tumor board. 
Amputation in extremity soft tissue sarcoma
Nowadays, limb-salvage can be achieved in most ESTS patients, even in those pa-
tients with locally advanced tumors. However, when limb-salvage treatment fails, am-
putation of the affected limb is the only treatment-option that remains.28-30 The level 
of amputation is mainly determined by the extensiveness of the tumor. However, also 
patients' functional outcome following the amputation should be considered. The 
involvement of a rehabilitation specialist at an early stage in the amputation decision-
process facilitates the determination of adequate amputation levels, a discussion re-
garding potential prosthesis use in the future and a patient-tailored postoperative 
rehabilitation program which all will improve the patients' functional outcome fol-
lowing the amputation. 
Limb-amputation in the metastatic setting should be reserved for patients suffering 
from severe symptoms of the local tumor, as survival following palliative amputation 
is generally poor, i.e. <8 months.28,29
Histology based treatment
Approximately 50 histologic STS subtypes are identified in the latest World Health Or-
ganization classification31, and therefore a histology based treatment seems to have a 
large potential for these patients. For instance, the proven radiosensitivity of myxoid 
liposarcomas led to the standardization of preoperative EBRT in these patients.32,33 
Besides, a preoperative hypofractionated, 5x5 Gy, EBRT regimen followed by surgical 
resection of the tumor within one week was found to be effective in myxoid liposar-
comas of the extremities.34 As a result of this, a radiotherapy dose reduction study in 
myxoid liposarcomas was initiated (DOREMY-study, NCT02106312) and first results are 
awaited. The dose reduction of preoperative EBRT, to a total dose of 36 Gy, in these 
tumors must be proven to be oncologically safe, and alongside, this dose reduction 
might result in a decreased major wound complication risk in this specific subtype.
As mentioned above, neoadjuvant chemotherapy is currently under ongoing inves-
tigation for high risk localized ESTS. In the metastatic setting the chemotherapy is 
patient-tailored and among others based on the histologic subtype. Subsequently a 
study was conducted randomizing high risk localized ESTS patients into a standard-
ized neoadjuvant chemotherapy regimen (control arm) or into a histotype-tailored 
regimen. Surprisingly, no survival benefit for the histotype-tailored regimen was 
shown.35 Further studies regarding the sensitivity to (neo)adjuvant chemotherapy 
regimens for specific histologic subtypes are warranted.36 
Metabolic and histopathological responses in pretreated extremity soft 
tissue sarcoma
The evaluation of treatment efficacy through the measurement of treatment re-
sponses will take a larger part in the contemporary treatment of ESTS, as the use of 
neoadjuvant treatment regimens i.e. chemotherapy, hyperthermic isolated limb per-
fusion and/or radiotherapy is rising. This response evaluation either prior to surgical 
resection of the tumor through imaging modalities or following the surgical resection 
through the histopathological evaluation of resection specimens needs to be stand-
ardized and validated. 
The validation of parameters to evaluate the metabolic tumor activity on fluorine-
18-fluorodeoxyglucose positron emission tomography with computed tomography 
(18F-FDG PET-CT) scans needs to be accompanied by the validation of volume of inter-
est (VOI) delineation techniques. The VOI used directly affects the values measured for 
the various parameters. The search for an robust and easy to implement VOI deline-
ation technique for these heterogeneous tumors accompanied by the identification 
of the most predictive PET derived parameter within this VOI is needed. Alongside 
these advancements in PET imaging, also progression in magnetic resonance imaging 
(MRI) are expected. A recent feasibility study in 11 lower ESTS patients who underwent 
preoperative chemoradiotherapy showed that it might be possible to predict histo-
pathological response using dynamic contrast-enhanced MRI.37 
The standardization of the histopathological examination of pretreated STS by the 
European Organization for Research and Treatment of Cancer-Soft Tissue and Bone 
Sarcoma Group (EORTC-STBSG), including a 5-tier response score38 is a step forwards. 
However, further research needs to demonstrate the predictive value of this response 
score. Several studies including high risk localized ESTS patients whom are treated 
with neoadjuvant chemotherapy are currently ongoing. Hopefully, the results of the 
histopathological examination of these tumors will provide more insight in the re-
sponse of these localized tumors including the relevance of the response induced 
by the neoadjuvant treatment. Hence, a good or excellent histopathological tumor 
response in a high risk localized tumor might result in a prolonged overall survival as 
micro metastases, not yet visible on the staging CT-chest scan, are treated as well. In 
contrast, a poor histopathological response of the primary tumor might be a reason 
to intensify the local treatment or to choose an alternative chemotherapy regimen in 
case of development of distant metastases during follow-up. 
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After the validation of both metabolic and histopathological responses in pretreated 
ESTS, it might be possible to alter the standardized treatment regimen into a patient-
tailored approach based on treatment efficacy as measured at the response evalua-
tion. 
Centralization of ESTS treatment
The treatment of ESTS has changed significantly over the past decades, from abla-
tive surgery in the mid-1980s to a multimodality limb-saving approach including, ra-
diotherapy, hyperthermic isolated limb perfusion, neoadjuvant chemotherapy and 
extensive surgical resections combined with plastic surgical reconstructions. These 
advancements in ESTS treatment have complicated the decision making process and 
subsequently differences in treatment approaches and outcome have originated be-
tween high-volume and low-volume (<10 resections annually) hospitals.39,40 A recently 
published study showed less positive surgical margins and even an improvement in 
overall survival for STS patients treated in high-volume hospitals. Furthermore, adher-
ence to clinical practice guidelines was found to be associated with an increase in 
progression-free and overall survival.41
In the future, further centralization of ESTS treatment will facilitate an evidence based 
patient-tailored treatment following discussion in a multidisciplinary tumor board. 
Consequently, this will contribute to a further improvement in the treatment and out-
come of STS patients. Besides, further centralization of daily sarcoma care strengthens 
the opportunities to conduct further prospective research and to reduce treatment 
costs.42 In the Netherlands the treatment of STS patients can be further centralized 
into five specialized sarcoma-centers enabling clinicians to provide optimal sarcoma-
care.39 
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